

A Study of Glutathione in
Health and Certain Disease
States

by
Jack Lewis Edwards

For Reference

TO BE TAKEN FROM THIS ROOM

FOR REFERENCE

NOT TO BE TAKEN FROM THIS ROOM

CAT. No. 1935

LOWE-MARTIN CO. LIMITED

EX LIBRIS UNIVERSITATIS ALBERTAENSIS



THE UNIVERSITY OF ALBERTA

A STUDY OF GLUTATHIONE IN HEALTH AND CERTAIN
DISEASE STATES

A DISSERTATION
SUBMITTED TO THE SCHOOL OF GRADUATE STUDIES
IN PARTIAL FULFILMENT OF THE REQUIREMENTS
FOR THE DEGREE OF MASTER OF SCIENCE

FACULTY OF (ARTS AND SCIENCE)

by

JACK LEWIS EDWARDS B.Sc., M.D.

EDMONTON, ALBERTA

SEPTEMBER, 1953.



Digitized by the Internet Archive
in 2018 with funding from
University of Alberta Libraries

<https://archive.org/details/Edwards1953>

ACKNOWLEDGEMENT

I wish to express my gratitude to the John and Mary R. Markle Foundation through whose interest this work was made possible. I am deeply indebted to Dr. D.R. Wilson for his guidance, suggestions and advice, and to Dr. R.E. Bell, Dr. Jules Tuba for their interest and assistance, and to Mr. E.S. Keeping, University of Alberta, for his assistance in the statistical analysis of the results. I wish to acknowledge the technical aid received from the laboratory staff and medical personnel of the University of Alberta Hospital, and General Hospital, and to thank the members of the Department of Medicine, Biochemistry and Physiology of the University of Alberta for their co-operation at all times.

ERRATA

Page 48: Line 4, "Hepatis" to read "hepatitis".

Page 18, "Hb" to read "Hb%".

Page 18, "Dehydroisoandriosterone" to read
"Dehydroisoandrosterone".

Page 24, "Prothrobin" to read "Prothrombin".

Appendices x "Mr. M.B." to read "Mrs. M.B."

TABLE OF CONTENTS

Page

A. Introduction	
i. For Orientation.	1
ii. History of Glutathione.	1
iii. Distribution of Glutathione.	2
iv. Synthesis of Glutathione.	2
v. Metabolism of Glutathione.	4
vi. Hydrolysis of Glutathione.	5
vii. Glutathione in Peptide Formation.	6
viii. Glutathione and Sulfhydryl Enzymes.	6
ix. Glutathione as a Regulator of Enzyme Action.	7
x. Glutathione and Ascorbic Acid.	8
xi. Glutathione in Relation to Cell Division and Growth.	8
xii. Glutathione and Ionizing Radiations.	9
B. Estimation of Glutathione.	12
i. The Method of Binkley et al.	12
ii. The Method of Thompson and Watson.	14
C. Normal Levels of Glutathione in Blood.	18
D. Glutathione in Blood Diseases and in Circumstances of Poor Blood Oxygenation.	
i. Blood Glutathione in Patient with Anemia.	20
ii. Glutathione Content of Erythrocytes in Patients with Pulmonary Disease.	21
iii. Glutathione Content of Erythrocytes in Patients with Heart Disease.	23.
iv. Discussion.	24.
E. Glutathione Content of Erythrocytes during Nitrogen Mustard Therapy	27
F. Glutathione and Diabetes.	
i. Introduction.	28
ii. Glutathione-Dehydroascorbic Acid and Diabetes.	31
iii. Glutathione-Intermediary Fat Metabolism Products and Diabetes.	32
iv. Previous Clinical Studies of Glutathione In Relation to Diabetes.	34.
v. Result of This Study of Glutathione in Relation to Diabetes.	36
G. Glutathione Levels in Relation to Pituitary Disease.	38
H. Glutathione Levels in Relation to Conditions Associated with the Adrenal Cortex.	41

	Page
I. Glutathione Content of Erythrocytes in Relation To Diseases of the Thyroid Gland.	44
J. Glutathione Content of Erythrocytes in Relation To Liver Disease.	47
K. Leukemia.	49
L. Pyrexia.	51
M. Active Erythrocyte Sedimentation Rates.	51
N. Pregnancy.	51
O. Miscellaneous Conditions Studied	53
i. Lobectomy.	53
ii. Renal Glycosuria.	53
iii. Wilson's Disease.	53
iv. Hemochromatosis.	54
v. Delayed Puberty.	54
vi. Non-tropical Sprue.	54
vii. Acute intermittent Porphyrinuria.	55
viii. Gout.	55
ix. Hypercholesterolemia.	55
x. Idiopathic Hypocalcemia.	55
xi. Possible DOCA Deficiency.	55
xii. Epilepsy.	56
xiii. Atopic Dermatitis.	56
P. Discussion of Results.	57
Q. Summary.	61
R. Appendices.	
i. Binkley et al's Method for Determination of Glutathione As Described in the Journal of Biological Chemistry. 188: 159 - 162, 1950.	i
ii. Method of Sullivan and Hess for Determining Cystine in Urine.	ii
iii. Mimeographed Copy of the Method as Received from Dr. Binkley. Estimation of Glutathione.	iii
iv. The Nitroprusside Method for the Determination of Blood Glutathione by Thompson, R.H.S. and Watson, D., J. Clin. Path. 5: 25 - 29, 1952	vii
v. Tables.	ix

INDEX OF FIGURES

<u>Figure</u>		<u>Opposite Page</u>
1.	Normal Glutathione Content of Red Blood Corpuscles.	18
2.	Glutathione Changes During Treatment of Pernicious Anemia - Mr. C.W.	21
3.	Glutathione Changes During Treatment of Pernicious Anemia - Mr. E.W.	21
4.	Glutathione Changes During ACTH Therapy.	39
5.	Glutathione Changes During Cortisone Therapy.	42
6.	Glutathione Changes During Treatment of Myxedema with Associated Diabetes Mellitis.	46
7.	Glutathione Changes During Treatment of Myxedema.	46

INDEX OF TABLES

Table No.

1. A Comparison of the Hydrolyzed Glutathione to the 500/580 ratio. (Binkley Method) page 13.
2. A Comparison of Duplicate Specimens of blood-method of Thompson and Watson page 15.
3. The Color intensity of acetoacetic acid (as ethylacetoacetate) produced in the method of estimation of Glutathione as described by Thompson and Watson. page 17.
4. Statistical Values of the Regression Line of mgm. Glutathione/100 cc. packed erythrocytes against age in Normal Individuals where y is glutathione content and x is age in years ($a = 60.17$) page 19.
5. Glutathione Content of Erythrocytes in Anemia opposite page 21.
6. Changes in Glutathione Content Occuring During treatment of Pernicious Anemia with Vitamin B 12 - Mr. F.H. opposite page 21.
7. Changes in Glutathione content Occuring During Treatment of Anemia with blood Transfusions r. opposite page 21.
8. Glutathione Content of Red Blood Corpuscles In Pulmonary Disease opposite page 23.
9. Glutathione Changes in Red Blood Corpuscles During the Administration and Deprivation of Oxygen Therapy in a case of Pulmonary Emphysema. opposite page 23.
10. Changes in Glutathione Content of Red Blood Corpuscles following improvement in pulmonary Function after Nitrogen Mustard Therapy for Bronchogenic Carcinoma. opposite page 23.
11. Glutathione Content of Erythrocytes in Patients with Heart Disease opposite page 23.
12. Glutathione Content of Erythrocytes of Cord Blood At Birth. opposite page 24.

Table No.

13. Glutathione Content of Erythrocytes During Nitrogen Mustard Therapy.opposite page 27
14. Glutathione Content of Erythrocytes Following 10 mgms. Nitrogen Mustard.opposite page 27
15. Glutathione Content of Erythrocytes in Patients with Diabetes Mellitis. 1.....between pages 35 & 36.
16. Statistical values of the Regression Line of mgms. Glutathione/100 cc. packed cells against age in Cases of Diabetes mellitis where y is glutathione content and x is age in years ($a = 53.9$).opposite page 36.
17. Changes in Glucose Tolarence Test and Serum Uric Acid levels as a Result of ACTH Therapy (25 mgms. I.V. daily) for 5 days - Mr. M.L. opposite page 39.
18. Glutathione Content of Erythrocytes in Patients showing hyperfunction of the Adrenal Cortex opposite page 43.
19. Glutathione Content of Erythrocytes in Patients with Thyrotoxicosis.opposite page 45.
20. Glutathione Content of Erythrocytes During Tapazole Therapy for Acute Thyrotoxicosis - Mr. N.M. opposite page 45
21. Changes in Glutathione Content of Erythrocytes During Tapazole Therapy for Acute Thyrotoxicosis...r.Miss.E.C.....opposite page 45.
22. Glutathione Content of Erythrocytes in Patient with Hypothyroidism -opposite page 45.
23. Glutathione Content of Erythrocytes. Acute Virus Hepatitis.opposite page 47.
24. Glutathione Content of Erythrocytes in Liver Diseases other than of Viral originopposite page 48.
25. Glutathione Content of Blodd in Myelogenous Leukaemia. opposite page 50.
26. Glutathione Content of Blodd and Erythrocytes During x-ray therapy in a Case of Chronic Lymphatic Leukaemia.opposite page 50.

Table No.

27. Glutathione Content of Erythrocytes in
Patients with Acute Pyrexia. opposite page 51.
28. Glutathione Content of Erythrocytes in Diseases
Associated with Elevated Erythrocyte Sedimentat-
ion Rates.....³/₄ opposite page 51.
29. Glutathione Content of Erythrocytes During and
Following Pregnancy.opposite page 52.
30. Glutathione Content of Erythrocytes in one
Case before and after Lobectomy page 53.
31. Glutathione Levels in a Case of Wilson's Disease
During BAL Therapy page 54.
32. Glutathione Content of Erythrocytes in Patients
with Atopic Dermatitis. page 56.
- Normal Glutathione Content of Erythrocytes
Appendices page ix.
- Glutathione Content of Erythrocytes in Conditions
Not Shown in the Other TablesAppendices Page x.


INTRODUCTION

For Orientation

This investigation was originally intended to study glutathione in relation to diabetes as a result of the discovery of glutathione protection against alloxan diabetes. It was proposed to study blood levels of glutathione in all types of diabetic patients, in those patients showing the complication of diabetes and in those diseases which tended to make diabetes more severe. When it was realized that glutathione is contained primarily in the erythrocytes and not in the plasma it was felt that a measure of the glutathione content of the erythrocytes was of more value than blood levels of glutathione. It was then discovered that in certain disease states there was an alteration in glutathione content of erythrocytes which will be reported. Since the study was originally intended to study the etiology of diabetes in relation to glutathione, the reader will find many references to diabetes in the discussions of other diseases.

History of Glutathione

Glutathione was isolated by Hopkins (1) in 1921 who showed that it was very widely distributed in living cells. He stated it was a dipeptide containing cysteine and glutamic acid. The following formula was worked out by Quastel, Stewart and Tunnicliffe in 1923.



2.

Hunter and Eagles (2) in 1927 suggested that glutathione might be a tripeptide and that serine might also be a constituent of the molecule. In 1929 Hopkins (3) reinvestigated his original work and found that glutathione was a tripeptide containing cysteine, glycine, and glutamic acid. He succeeded in finding a method for the ready isolation of glutathione in the pure crystalline state. Kendall, McKenzie and Mason in 1929 (4) confirmed the work of Hopkins that glutathione was a tripeptide and that it was formed from cysteine, glycine and glutamic acid.



Distribution of Glutathione

Glutathione is found almost exclusively in the intracellular fluid. In the blood it is found in the red blood corpuscles and is mostly in the reduced form. Of interest is the high concentration of glutathione in the lens of the eye (5,6), and its marked reduction when a cataract forms (5,7). The spinal fluid, normally being devoid of cells is reported not to contain glutathione (8).

Synthesis of Glutathione

A rapid incorporation of the N15 from labelled glycine and glutamic acid into the glutathione of livers and small intestines of intact animals was demonstrated by Waelsh and Kittenberg (9,10). They showed the half lifetime of glutathione in the livers of rats and rabbits to be about two to four hours. Braunstein et al (11) succeeded in demonstrating the synthesis of glutathione from the three component aminoacids in tissue slices of rat livers. Block et al


(12,13,14,15) showed that the supernatant solution of pigeon liver homogenates contained the enzyme system responsible for the introduction of labelled glycine into glutathione. They also showed that C14 glycine, N15 glutamic acid and N15 glycine result in the formation of labelled glutathione. It was found also that adenosine triphosphate markedly accelerated the aerobic synthesis of glutathione in liver homogenates. Anderson and Mosher (16) have demonstrated that the intestinal mucosa may also be a site of glutathione synthesis using S35 labelled DL.cystine. The maximum incorporation of cystine sulfur into liver glutathione they estimated to take place in the rat in less than three hours. Linden and Work (17) found that rats given a deficient diet of the sulfur containing aminoacids had reduced (reduced and total) glutathione values. Binkley et al (18) have found that the giving of insulin caused a marked decrease of glutathione in the liver. The glutathione content of blood has been reported to fall in hepatectomized animals and in patients with acute hepatic disease which suggested that the glutathione of erythrocytes was derived from the liver. However, the possibility has not been excluded, as Binkley states, that the role of the liver might be to furnish the constituent aminoacids for the synthesis of glutathione by erythrocytes and other tissues, or insulin may act as a stimulant for the removal of glutathione from the liver by the erythrocytes. Of interest is the work of Kinsey and Merrian (19), who, using glycine with radioactive C14 were able to show glutathione synthesis in situ in the lens. Binet et al (20) have also shown that when the suprarenal gland is perfused

with cystine and glutamic acid there develops a marked increase in the glutathione content of the perfused gland (200 mgms. over the control gland) and also a marked increase in glutathione content of venous blood over arterial blood.

Metabolism of Glutathione.

Glutathione in the extracellular fluid may be oxidised by the catalytic action of copper (21). Keilin (22) showed that glutathione inside the cells maybe oxidised by the catalytic action of the cytochrome oxidase-cytochrome C system. Ames and Elvehjem (23,24) also found that reduced glutathione could be oxidised by an enzymatic system involving cytochrome C. The glutathione oxidase system is strongly inhibited by heat, cyanide, diethyldithiocarbonate and ~~iodacetate~~. They found that co-enzyme 1 increased the rate of enzymatic oxidation of reduced glutathione in the absence of cytochrome C and ~~decreased~~ the induction period either in the presence or absence of cytochrome. They found that adenosine triphosphate had no effect on the enzymatic oxidation of reduced glutathione. Ascorbic acid was found to catalytically stimulate the oxidation of reduced glutathione by cell free tissue preparations both in the presence or absence of cytochrome C. Purr (25) showed that glutathione could be oxidized by hydrogen peroxide and peroxidase. Hopkins and Elliott (26) showed that the livers of well fed animals reduced oxidized glutathione rapidly, and the reduced glutathione was also rapidly oxidized and found also that these processes were greatly reduced in the livers of starved animals- and indication that reduction was correlated with the oxidation of metabolites.

Mann (27) showed that glutathione is reduced by glucose in the presence of glucose dehydrogenase prepared from liver. The reaction proceeds slowly, but can be greatly accelerated by an activator which can be extracted from liver. Meldrum and Tarr (28) showed that glutathione is reduced both aerobically and anaerobically by the Warburg --Christian enzyme -- co-enzyme system in the presence of hexosemonophosphoric acid.



TPN is co-enzyme II - The Warburg-Christian co-enzyme is present in red blood corpuscles.

Hydrolysis of Glutathione

Binkely et al have studied the hydrolysis of glutathione very extensively. They (29) believe the hydrolysis of glutathione to cysteine is a two-step process involving the intermediary formation of cysteinylglycine. No γ -glutamylcysteine was found. The enzyme responsible for the hydrolysis of glutathione to cysteinylglycine was, in the rat, they found limited to the kidney and intestine. The enzyme responsible for the hydrolysis of cysteinylglycine was found in muscle and liver as well as in kidney, and they felt it probably occurred in all tissues. Their results (30) suggested that a physical as well as a functional relationship exists between the glutathionase and cysteinylglycinase of kidney tissue. Cysteinylglycinase has been found to be activated by manganous, cobaltous and ferrous ions. It has been found (31) that glutamine is required for the hydrolysis of glutathione by enzymes of kidney tissues. The site of

action of glutamine was upon the first step -the hydrolysis to cysteinylglycine-. Since glutamine is not hydrolyzed by the system, they have concluded that glutamine was acting as a co-enzyme.

Penicillin and bromosulfalein were found to be inhibitors of the hydrolysis. They believe (32,33,34) glutathionase is a lipoprotein and cysteinylglycine maybe a pentose nucleic acid.

Glutathione in Peptide Fermentation.

Hanes, Hird and Isherwood (35,36) have shown that glutathione will react with various aminoacids in the presence of an enzyme from kidney and other tissues to form new peptides containing glutamic acid. Their evidence shows that the new peptides formed were γ -glutamyl peptides and that the reaction consisted of the transfer of the γ -glutamyl group from its linkage in glutathione to linkage with the amino group of an "acceptor" aminoacid. They suggest, as also have Fruton et al, (37) that glutathione may participate in enzyme-catalyzed transamidation reactions in protein synthesis.

Binkley (32) suggests, because of the limited distribution of glutathionase, that the hydrolysis of glutathione is intimately concerned with absorptive processes, and in particular, with the function of the intestine and kidney.

Glutathione and Sulfhydryl Enzymes

Sulfhydryl groups are common to many enzymes, and inhibitors of these enzymes react by combining with the -SH group.

e.g. heavy metal, or by causing oxidation of the -SH group.

Glyoxalase is the only enzyme system known in which glutathione acts as a co-enzyme. Hopkins and Morgan (38) have shown glyoxalase is

widely distributed in living organisms and the activity of the enzyme is limited by the amount of glutathione present in the cells. Barron and Singer (39,40) showed that a great many enzymes concerned with carbohydrate, fat and protein metabolism were -SH enzymes. Kremsky and Racher (41) have shown that glyceraldehyde -3- phosphate dehydrogenase contains a firmly bound prosthetic group which they have identified as glutathione by several independent tests. Roughton and Clark (42) state that glutathione is an activator of carbonic anhydrase. Whenever the thiol groups of these enzymes are attacked by agents which destroy the -SH groups, glutathione will restore the SH groups by withdrawing the heavy metal or by reducing the oxidized -SH groups.

Glutathione as a Regulator of Enzyme Action

Barron et al (43) by measuring the respiration of sea urchin sperm treated with a variety of -SH reagents: oxidizing, alkylating and mercaptide forming agents, found that when these reagents were employed at low concentrations, just enough to combine with, or oxidize the soluble groups present in the cell, there was an increase in cell respiration. As the concentration of the -SH reagents was increased, the fixed -SH groups, those in the side chains of the protein, were attacked, and inhibition of respiration ensued. They (43,44) postulate therefore, that there are, in living cells, two types of thiol groups: the soluble thiol groups, mostly glutathione, which belong to the regulatory mechanisms of cellular metabolisms; and the fixed thiol groups, which are in the side chains of the proteins. Thiol enzymes belong to this latter group.

Glutathione and Ascorbic Acid

Glutathione is known to prevent the oxidation of ascorbic acid (45). Barron states (46) that both substances are universally distributed in living cells, mostly in their reduced state; both exist in greater concentrations in embryonic tissue, where the synthetic processes occur with greater intensity and both are sluggish oxidation-reduction systems, not oxidized in atmospheric oxygen unless in the presence of a catalyst. In the absence of ionic copper in the cells, where copper is mostly bound to aminoacids or protein, glutathione may protect ascorbic acid from oxidation.

Glutathione in Relation to Cell Division and Growth

Rapkin, (47,48,49) twenty years ago, found that glutathione was associated with cell division and he showed that there was a marked increase in the glutathione content of fertilized sea urchin eggs just before cell division. Addition of $HgCl_2$ stopped mitoses completely. Voegtlin and Chalkley (50) showed that glutathione added to ameba proteus caused increased nuclear and cell division and more polynucleated cells, showing that glutathione had more effect on nuclear division than on cell division. Rapkin postulated that acceleration of the processes of cell division and cell growth was due to a decrease in the oxidation-reduction potential in the cell, i.e. an increase in the reduction intensity. He believed that the increased -SH groups were produced by a reversible denaturation of intracellular proteins which transformed masked and sluggish -SH groups into freely reactive -SH groups. Binet et al (51,52) found in plant tumors there was a marked increase

in glutathione content, and that the increase of glutathione is a function of the rapidity of growth of the tumor. Brachet (53) agrees with Rapkine's postulation. Glutathione has been shown to be a nutritional requirement of Hemolytic streptococci (54) and *Neisseria gonorrhoea*(55). The growth inhibiting action of -SH reagents on cultures of *Escherichia coli*, *Eberthella typhosa* and *Staphylococcus aureus* could be combated by the addition of cysteine and glutathione, but not by cystine or methionine (56).

Glutathione and Ionizing Radiations

Glutathione and other thiols have been studied extensively by different investigators in relation to ionizing radiations. Barron(57) postulated, in 1944, that ionizing radiations would rapidly oxidize the thiol groups of cells. Kinsey (58) previously, in 1935, showed that X-rays had a destructive effect on aqueous solutions of glutathione. Barron and Flood (59) found that glutathione was readily oxidized by X-rays, beta rays and gamma rays. Barron et al (60,61) showed that dilute solutions of sulfhydryl enzymes showed reduced activity on irradiation by small amounts of X-rays. When the inhibition was partial, the enzyme was reactivated on addition of glutathione showing that the inhibition was produced by oxidation. Le May (62), studying the succinic oxidase system as well as its component enzymes in rat kidneys following irradiation, found no inhibition, and he questions any selective in vivo effects of moderate doses of irradiation on -SH enzymes. Dale and Davies (63) have shown that apart from any possible reversible oxidations that

may occur, there are also irreversible changes produced by X-rays leading to the liberation of hydrogen sulfide. This has been shown to occur with cysteine and glutathione. Feinstein (64) demonstrated that cysteine and glutathione, if added before irradiation, prevented the reduction in viscosity of alkaline nucleoprotein solutions. Fischer et al (65) found that the reduced glutathione content of blood, liver, heart, kidney or muscle was not lowered following fatal X-ray dosages in mice and guinea pigs. Peterson et al (66) found that in rats total body irradiation of 500 r generally caused a decrease in blood glutathione (mgms,%), associated with a drop in hematocrit, whereas, correcting for the hematocrit there was actually an increase in glutathione in the red blood corpuscles following irradiation. Patt et al (208) showed that cysteine and glutathione intravenously greatly reduced the sensitivity of rats and mice to lethal amounts of X-ray provided it was given before exposure. Chapman and Cronkite et al (67 -72) found that the survival rates of glutathione treated rats were greater than those not treated, and that these animals lost less weight, recovered weight more rapidly and withstood trauma better than the control animals. They found also that glutathione given before irradiation to mice seemed to protect the mechanisms which accelerate regeneration of the hemopoietic and myelopoietic tissues. They followed the clearance of intravenously given glutathione in dogs and found that the extra glutathione rapidly disappears from blood and that the distribution of this

glutathione is not uniform, but the highest concentrations were found in the liver, spleen and kidneys. They suggest that glutathione protection when given before irradiation, is due to it being concentrated in vital organs, liver, kidney and spleen. Shirai (73) has reported beneficial effects following glutathione treatment of thirty-two patients who were known to be suffering from roentgen intoxication as a result of X-ray therapy for uterine carcinoma. Mikaelson (74) has shown that glutathione prevents the development of radiation-induced chromosome aberrations. Fulton et al (75) have shown that glutathione appears to protect also the animals immune defensive systems from the effects of X-radiation or enhance them after they have been impaired as a consequence of the X-radiation.

ESTIMATION OF GLUTATHIONE IN BLOOD

There have been many methods developed for the estimation of glutathione (76-83, 85-89).

The method of Binkly et al (80) attempts to measure not only glutathione but also the products of its metabolism which are cysteinylglycine, γ -glutamylcysteine and cysteine. Cysteine is not found normally in blood. This method was attempted at first. (see appendix for details of methods as described). Many difficulties were encountered. Sodium-B-naphthaquinone-4-sulfonate which was old stock gave a cloudy solution instead of a clear solution as a new stock later gave. At the same time this reagent should be made up fresh daily, a fact which Binkley did not bring out in his articles. Sodium thiosulfate, also old stock, did not allow the final color reaction to remain stable long enough for reading purposes. When new stocks of these reagents were obtained these difficulties disappeared. Their method (80) was very briefly described, (see appendix), subsequently many interpretations of the different procedures could be found. It was difficult to decide where, in the method of Sullivan and Hess (84) (see appendix) one should start, and after consultation with others, it was decided that the addition of 5% NaCN was not necessary. After a great deal of work without satisfactory results, I then wrote to Binkley, who sent me mimeographed copies of his method. (see appendix) Here many of the steps are described in more detail and amounts and concentrations of reagents changed from that described previously.

THE HISTORY OF THE

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

Their readings, as reported, were made using a Coleman junior clinical spectrophotometer. This equipment was not available at the University of Alberta Hospital and a Beckman Model DU spectrophotometer was used. A standard solution of 0.5 mgms/cc glutathione with this equipment gave a reading of around 80% light transmission at 540 mu. which was not in the range of greatest accuracy for reading; whereas using their equipment, they obtained readings of 53-55% light transmission for a solution of 0.5 mgms/cc glutathione. In order to concentrate the final volume to increase the color concentration, the concentration of the reagents of Sullivan and Hess were increased, and the volume of each added, was decreased proportionately so that the final volume was only 12 cc instead of 17 cc. The readings then for 0.5 mgms/cc glutathione were from 41-44% transmission at 540 mu. but the final color reaction was not stable long enough and it was felt at these concentrations the reagents were not stable. Another difficulty experienced was obtaining a constant 500/580 ratio for cysteinylglycine and cysteine (see table 1). For different concentrations of cysteinylglycine (hydrolyzed glutathione) the 500/580 ratio should have been constant.

<u>Mgms. GSH Hydrolyzed to Cysteinylglycine</u>	<u>500/580 Ratio</u>
0.1	2.2
0.25	1.4
0.5	1.2

Table 1 A comparison of the hydrolyzed Glutathione to the 500/580 ratio (Binkley method).

With standard solutions of cysteine hydrochloride the 500/580 ratio varied from 4.25 to 5.1. The relative concentrations of cysteine and cysteinylglycine are read from a graph of the 500/580 ratios. Binkley et al (5) found the 500/580 ratios for cysteine to be 3.4 and for cysteinylglycine to be 1.3 and the composition of a given solution would be found from a graph using these two values. Without constant values for the 500/580 ratio of pure solutions of cysteinylglycine and cysteine it would be impossible to make such a graph without a large percentage error. Their results (5) show errors in cysteinylglycine and γ -glutamylcysteine ranging from 25% to almost 50%. For the reasons given above this method was discarded.

The method of Thompson and Watson (82) was then attempted with success. This is a nitroprusside method which was first described by Fujita and Numata in 1939, and later modified by Bruckman and Wertheimer (13) in 1947. Thompson and Watson have also modified the method in order to increase the stability of the reagents, and increase the color intensity. After the production of color the solution was transferred to Helige 510 tubes and read in the Evelyn Photoelectric Colorimeter, using the Freier-Larsen adaptor and a 515 filter. The final color remained stable long enough for one to get an accurate reading. As they suggested a standard solution of glutathione was included in each series of blood estimations. In almost every series one recovery experiment was carried out and the recoveries were always between 90 and 102 %. A series of duplicate determinations on blood gave results within 2 mgm % (see table 2).

	<u>No.1</u>	<u>No.2</u>
1.	26.0	26.0
2.	26.8	27.6
3.	32.0	32.8
4.	32.4	31.6
5.	18.4	19.2
6.	23.2	22.8
7.	21.6	20.4
8.	21.4	22.0
9.	22.2	22.8
10.	26.8	26.4
11.	20.8	21.6
12.	24.4	25.2
13.	26.8	25.8
14.	23.6	24.2
15.	28.8	28.0
16.	36.0	34.8
17.	38.0	37.6

Table 2 Comparison of duplicate specimens of
 blood-method of Thompson and Watson.

The results with the nitroprusside method are slightly lower than those by iodometric method as shown By Thompson and Watson (82). They state the slowly developing nitroprusside reaction given by acetoacetic acid roughly equivalent to blood levels of 4 mgms/100 ml. gave no measurable color at 30 seconds, although by 90 seconds a significant degree of color had developed. Kety et al (252) studied total ketones in diabetic acidosis and reported that in severe diabetic acidosis there were 38.5 to 90.6 mgms % with an average of 66.3 mgms % total ketones present. In diabetic coma they reported 47.7 to 132.5 mgms % with an average of 98.4 mgms % total ketones. The effect of acetone to 100 mgms. % was studied and showed no color reaction, however, ethylaceto acetate gave a marked color reaction even at levels of 25 mgms % acetoacetic acid (see table 3). This must definitely be taken into consideration in reporting the results of patients with diabetic acidosis as will be shown later.

<u>Acetoacetic Acid mgms. %</u>	<u>Color Intensity Compared with Glutathione Concentration</u>
100	20.0 mgms. %
80	16.8 mgms. %
50	13.6 mgms. %
25	9.6 mgms. %

Table 3 The color intensity of acetoacetic acid (as ethylacetoacetate) produced in the method of estimation of Glutathione as described by Thompson and Watson.




Figure I

NORMAL LEVELS OF GLUTATHIONE IN BLOOD

Most investigators have expressed glutathione values in mgms. %. It soon occurred to us, that, since the glutathione is contained almost exclusively in the intracellular space, a correction should be made for differences in the concentration of erythrocytes in the blood (hematocrit). All glutathione values in this investigation are, therefore, expressed as mgm. glutathione/100 cc. packed erythrocytes. We are therefore showing the comparative amount of glutathione in each erythrocyte, and can compare the amount present even where there is a difference in the hematocrit.

Normal values of glutathione were determined from fifty one people ranging in age from eighteen months to eighty years (see figure 1 and appendix). Most of the patients taken as normal were either young people who had had poliomyelitis, but, who were past the acute stage by three or four months, and who were in hospital for treatment, or older people in hospital with fractures. They were all seen and checked for any other illnesses they might have. Results expressed as mgm. glutathione/100 cc. erythrocytes ranged from 51 mgms. to 81 mgm. The average age was 37.4 years and the average glutathione value was 64.0 mgms./100 cc. erythrocytes. As it may be seen from figure 1, there is a suggested increase in glutathione content of erythrocytes with increasing age, which can be shown statisically (see table 4). The value of t is 2.291 with 48 degrees of freedom. The 5% value is 2.01. The probability of deviation from 0 as great as that found was 0.04 which is significant.

This slope is significantly different from 0 at the 5% level.

Age	$y = a + b x$			Mgm. GSH/100 cc. R.B.C.'S
5	60.17	+ 0.1024	X5	60.68 mgms.
20	60.17	+ 0.1024	X20	62.22 mgms.
40	60.17	+ 0.1024	X40	64.27 mgms.
60	60.17	+ 0.01024	X60	66.31 mgms.
80	60.17	+ 0.1024	X80	68.36 mgms.

Table 4 Statistical Values of the Regression Line of mgm. Glutathione/100 cc. packed erythrocytes against age in Normal Individuals where y is glutathione content and X is age in years ($a = 60.17$)

GLOTHATHIONE IN BLOOD DISEASES AND IN CIRCUMSTANCES
OF POOR BLOOD OXYGENATION

(1) Blood Glutathione in Patients with Anemia.

Glutathione has been studied extensively in relation to blood diseases. Since glutathione is contained in the blood elements and not in the plasma, it is necessary when considering blood levels to correct for the hematocrit reading. Gabbe (90) in 1929 showed in anemia the reduced glutathione content of red blood cells was greater than normal. He showed that in animals the removal of blood caused a reduction of blood glutathione, whereas the amount in each corpuscle went up. He suggested that the purpose of glutathione was not so much for the metabolic needs of the cells, but for assisting in the oxidation and reduction of hemoglobin. Varela et al (92) in 1930 reported low blood glutathione levels in hypochromic and pernicious anemias, but they did not correct for the hematocrit. Since then many investigators (93 - 100) have studied glutathione in relation to anemias and the differences in their findings are mostly due to the fact that some corrected for differences in hematocrit and others did not. Unless corrected for hematocrit the glutathione levels in blood were found to be normal or low whereas if corrected for hematocrit the glutathione content of the red blood corpuscles was found to be above normal. Bickel (94) has shown that hemorrhages in rabbits and man cause a fall in glutathione corresponding to the fall in erythrocytes, but afterwards glutathione values rise more rapidly than the erythrocytes, so that




Figure 2




Figure 3

Case No.	Name	Age	Hg.	GSH/mgms.%	Hem.	Mem. GSH/100 cc. RBC	Comments & Diagnosis
1.	Mrs. H.C.	75	59%	28.8	32	80	Diabetes and Uremia
2.	Mrs. H.K.	63	61% (8.8)	30.2	34	95	Diabetes and Uremia
3.	Mr. O.L.	64	57% (8.3)	19.2	28	69	Gastric Ulcer with Haemorrhage
4.	Mr. R.L.	64	47% (6.8)	17.8	27	66	Retropéritoneal Sarcoma Pyrexia
5.	Mrs. B.	80	40%	18.6	20	93	Primary Essential Myeloid Metaplasia.
6.	Mrs. I.F.	47	42% (6gm.)	38.8	30	129	$\frac{3}{4}$ Gastrectomy 5 years ago. Improved on Iron.
7.	Mrs. V.A	72	48%	17.8	30	59	Idiopathic Hypocalcaemia
8.	Mrs. G.	62	56% (8.2)	19.8	30	66	Multiple Myeloma - Pyrexia
9.	Mr. F.E.	80	52% (7.6)	26.4	30	88	Associated diabetes mellitis
10.	Mr. R.C.	68	59% (8.6)	32.4	35	93	Hypertensive Heart Disease with failure
11.	Mrs. L.H.	71	62% (9.0)	32.8	33	99	Multiple Myeloma, Pyrexia
12.	Mrs. F.K.	44	40% (5.8)	37.8	35	108	Hypochromic Anemia
13.	Mrs. D.L.McD	43	52%	33.2	32	104	Hodgkin's Disease
14.	Mr. A.K.	41	50% (7.2)	45.2	23	197	Bone Marrow Normal
15.	Mr. L.P.	39	40% (5.8)	40.0	31	129	Rheumatoid Arthritis
16.	Mr. C.W.	80	32%	15.6	15	104	Pernicious Anemia
17.	Mr. E.W.	43	43%	16.6	21	80	Pernicious Anemia
18.	Mr. T.M.	53	59%	21.2	33	64	Untreated Diabetes
19.	Mrs. S.J.	28	69%	25.6	30	80	Hypothyroidism and Diabetes
20.	Mr. E.D.	39	62% (9)	32.8	30	109	Hypothyroidism
21.	Mrs. O.	60	73	34	36	95	Probably Hypopituitarism
22.	Mr. A.K.	41	68% (9.8)	37.6	31	121	Chronic Lymphatic Leukaemia
23.	Mr. C.S.	61	62% (9)	22.2	32	74	Possibly Multiple Myeloma
24.	Mr. P.O.	84	51% (7.4)	29.8	29	103	Prostatic Ca. with Metastasis
25.	Mr. I.S.	40	66%	34.0	38	90	Diabetes untreated. Hypertension
26.	Mr. F.H.	63	31% (5.1gms.)	17.2	17	101	Pernicious Anemia.

Table 5 - Glutathione Content of Erythrocytes in Anemia.

Mr. F.H.

Age 62.

Date	Hb.%	GSH mgm.%	Hematocrit	Mgm. GSH/100cc. RBC
21.4.53	31%	17.2	18	101.2
30.4.53	57%	20.4	26	79
7.5.53	69%	17.2	36	46
14.5.53	79%	21.8	39	56

Table 6 - Changes in Glutathione Content Occuring during treatment of Pernicious Anemia with Vitamin B 12.

Name	Date	Amount of blood received	Hb.%	GSH in mgms.%	Hem.	Mgm.GSH/100cc. Packed RBC
Mrs. H.K.	27.1.53	2000 cc. in	61%	30.2	34	95
	5.2.53	4 days	84%	29.8	40	75
Mrs. D.L.	27.1.53	1500 cc.	64%	33.2	32	104
McD.	13.2.53		100%	30.4	48	63

Table 7 - Changes in Glutathione Content Occuring during treatment of anemia with blood transfusions.

the "glutathione index" is increased. In four patients with pernicious anemia he found the "glutathione index" to be very high, being highest where the number of erythrocytes the lowest. As the erythrocytes increased with treatment the blood glutathione (in mgms.%) increased also, but slower than the erythrocyte count so that the "index" decreased.

In this study there were twenty-six patients with anemia (see table 5). The range of glutathione values obtained was from 59 - 197 mgms/100 cc. red blood corpuscles, with an average of 96 mgms/100 cc. red blood corpuscles. Three cases of pernicious anemia were followed while receiving vitamin B12 (see figure 2 and 3 and table 6). It will be noted that as the hematocrit and hemoglobin rose in each case the glutathione content of the red blood corpuscles fell for about the first two weeks, and then began a slow rise. However, in the case of Mr.C.W. (figure 2), even after eleven weeks, when he had returned to active work, the glutathione content of the red blood corpuscles had not returned to its original high level. It might be that the increased levels, after about two weeks, could be correlated with increased activity as the patients improved. In two cases of anemia associated with other conditions (see table 7) there was a marked drop in the glutathione content of red blood corpuscles following elevation of the hematocrit and hemoglobin by means of blood transfusions.

(2) Glutathione Content of Erythrocytes in Patients with Pulmonary Disease.

Condition associated with poor oxygenation of the blood have

been studied in relation to glutathione, Gurevich (101) stated that in pulmonary and cardiac disorders the changes in reduced or total glutathione were not specific for any given disorder. Klotz (102) found that the glutathione content of red blood corpuscles was increased in congestive heart failure, and returned to within normal limits on digitalis therapy. Aisenberg and Khatskevich (103) reported that during the first and second stages of decompensation in congestive heart failure the glutathione content of red blood corpuscles rose. Blyakher (104) also reported high glutathione levels in decompensated heart disease. Rabboni and Buttitta (105) found in animals, following lobectomy and pneumonectomy, an increase in blood glutathione with only a slight increase in hematocrit. Kosyakov (106) and Hosoi (107) found increased glutathione content of erythrocytes during anoxemia and asphyxia respectively. Chervyakovski and Bruk (108) stated that in any condition leading to severe cyanosis, the glutathione content of blood is elevated. Increased glutathione content of erythrocytes at high altitudes have been reported by Paskaeu (109) and others (110,111,112). Vacca (113) also found high glutathione content of erythrocytes at lowered barometric pressures and believed this due to more newly formed erythrocytes in the circulating blood, which he thought might be richer in glutathione than the older erythrocytes. High glutathione levels have been reported in carbon monoxide poisoning by Omura and Ohida (114) and by Yoshizawa (115).

In this study there were ten cases of pulmonary disease

Case No.	Name	Age	Hg.	GSH in mgms. %	Hem.	Mgm. GSH/100 cc. RBC	Comments and Diagnosis
1.	Mr. J.E.	68	89% (12.9)	49.2	48	103	Bronchogenic Ca. with Cyanosis
2.	Mr. A.J.D.	56	83%	27.6	36	77	Pulm. Fibrosis with Emphysema, Multiple Myeloma.
3.	Mr. E.N.	67	106% (15.5)	44	50	88	Marked emphysema with congestive heart failure.
4.	Mr. J.F.	66	86%	35.2	40	88	Marked emphysema with dyspnoea.
5.	Mrs. S.W.	72	107% (15.6)	52	54	96	Bronchiectosis, emphysema, cyanosis and heart failure.
6.	Mr. M.G.K.	48	105% (15.3)	39	50	78	Asthma, Bronchial.
7.	Mr. C.V.	53	99% (14.4)	41.2	48	90	Bronchial Asthma.
8.	Mr. J.C.	62	105% (15.3)	53.6	55	98	Chronic Pulmonary Fibrosis with cyanosis.
9.	Mr. J.C.	54	132% (19.2)	72.8	66	110	Severe Emphysema with cyanosis and Secondary Polycythemia.
10.	Mr. J.R.	78	104% (15gms.)	33.5	48	70	Emphysema. CO2 combining power 67.3 vol. %.

Table 8 - Glutathione Content of Red Blood Corpuscles in Pulmonary Disease.

Mr. K.S.
Pulmonary Emphysema.

Date	Time	Comments	GSH in mgms. %	Hem.	Mgms. GSH/100cc. RBC's
22.4.53	8 A.M.	Had been on continuous O ₂ for 6 days	38.8	59	66
24.4.53	8 A.M.	Taken off O ₂ following this determination	39.2	55	71.3
24.4.53	9 A.M.	Taking O ₂ only when absolutely required	40.4	58	69.7
24.4.53	11 A.M.	Taking O ₂ only when absolutely required	39.6	56	70.7
24.4.53	2 P.M.	Taking O ₂ only when absolutely required	38.6	55	70.2
25.4.53	8 A.M.	Taking O ₂ only when absolutely required	43.6	55	79.3
26.4.53	8 A.M.	Taking O ₂ only when absolutely required	47.2	59	80.0
27.4.53	8 A.M.	Taking O ₂ only when absolutely required	47.2	59	80.0
28.4.53	8 A.M.	Taking O ₂ only when absolutely required	46.8	60	78.0
30.4.53	8 A.M.	At 6 P.M. put back on continuous O ₂ On continuous O ₂ since 6 P.M. Apr. 28 O ₂ discontinued.	42.8	55	78.0
7.5.53	8 A.M.	Taking O ₂ only when absolutely required	41.2	58	71.0
14.5.53			41.0	57	72.0

Table 9 - Glutathione Changes in Red Blood Corpuscles During the Administration and Deprivation of Oxygen Therapy in a case of Pulmonary Emphysema.

Mr. J. E. (No. 1, Table 8)

Date	Comments	GSH in mgm. %	Hem.	Mgms. GSH/100cc. RBC
12.2.53	Markedly cyanotic and dyspnoea	49.2	48	102.5
20.2.53	Some Improvement	38.4	45	85.3
11.3.53	Markedly improved (no longer cyanotic)	22.8	39	58.4
17.3.53	Markedly improved (no longer cyanotic)	24.4	37	66.0

Table 10 - Changes in Glutathione Content of Red Blood Corpuscles following improvement in Pulmonary Function, Nitrogen Mustard Therapy for Bronchogenic Carcinoma.

Name	Age	Hg.	Diagnosis	GSH/mgms. %	Hem.	Mgms. GSH/100cc. RBC's
Miss N. MacD.	5	121%	Congenital Heart Disease no failure	35.0	52	67.3
Mrs. N. H.	60	69%	Prolonged Congestive Heart failure	29.6	31	98.1
Mrs. R. B.	48	74%	Mitral Stenosis with Congestive heart failure	24.8	35	70.3
Mrs. I. P.	41	73%	Mitral Stenosis, auricular fibrillation. Right heart failure.	44.4	42	105.7
Mrs. C. A.	52	79%	Hypertensive heart disease with failure and uremia.	32.4	39	83.1

Table 11 - Glutathione Content of Erythrocytes in Patients with Heart Disease.

(see table 8) with values of glutathione/100 cc. red blood corpuscles ranging from 70 -110 mgms. with an average of 86.8 mgms. One case (see table 9) of pulmonary emphysema was studied during the administration and withdrawal of oxygen. It will be noted that following the withdrawal of oxygen, the glutathione content of the red blood corpuscles rose, associated also with an elevation in hematocrit. This did not occur within the first six hours but had occurred within twenty-four hours. The rise might have been more rapid and more marked if he could have kept away from oxygen continuously. The return to continuous oxygen for thirty-six hours lowered both the glutathione content of blood (mgms.%) and the hematocrit, but proportionately, and there was therefore, no change in the glutathione content of the red blood corpuscles.

One case of improved pulmonary function, following nitrogen mustard therapy for bronchogenic carcinoma, was studied (see table 10). It is to be noted that there was a marked drop in the glutathione content of the erythrocytes associated also with a drop in the hematocrit. This drop in the glutathione content of erythrocytes was not due to the nitrogen mustard therapy, as will be shown later.

(3) Glutathione Content of Erythrocytes in Patients with Heart Disease.

Five cases of heart disease with failure were studied (see table 11). The values obtained ranged from 67.3 to 105.7 mgms. glutathione/100 cc. erythrocytes with an average of 85 mgms. for the five cases.

NEWBORNS

Name	GSH mgm. %	Hem.	Mgm. GSH/100 cc. RBC's	Comments
Baby McLeod	38.8	49	79	Placenta small and fibrotic. Mother very toxic
Baby Sloan	51.2	57	90	
Baby McLaughlin	45.2	55	82	Small baby cyanosed - small fibrotic placenta
Baby Clement	43.2	47	92	
Baby Campbell	43	52	83	
Baby New	29	46	63	
Baby Coombe	52.4	55	95	
Baby Paton	44.8	62	72	
Baby Danes	30.4	49	62	
Baby Hartley	36.8	57	65	

Table 12 - Glutathione Content of Erythrocytes of Cord Blood at Birth.

(4) Discussion.

Why should these conditions cause elevated glutathione levels in the erythrocytes ? In all these conditions the one common factor present, is the lowered oxygen carrying capacity of the blood, either because (1) there is a deficiency of hemoglobin as in the anemias; or (2) that the hemoglobin is unable to combine with oxygen as in the carbon monoxide poisoning; or (3) that there is poor oxygenation of the blood, as seen in certain forms of pulmonary disease, congestive heart failure and at high altitudes. Is the elevated glutathione level of erythrocytes to facilitate the oxygenation of hemoglobin, or the dissociation of oxygen from oxyhemoglobin, or is it to increase the efficiency of cellular metabolism under adverse conditions of oxygen pressure ? Handovsky (116) in 1930 stated that in conditions of oxygen deficiency there was an increased liberation of free glutathione, which would act as a hydrogen acceptor and oxidation would be replaced by dehydrogenation as a source of energy. Komissarov (117) states that in anemic hypoxemia, increased anaerobic oxidation occurs at the expense of glutathione and supplements the deficiency of oxidative processes. Gabbe (90) suggested that the glutathione content of erythrocytes was not only for the metabolic needs of the cells, but for assisting in the oxidation and reduction of hemoglobin.

Hughes (118) has shown that crystallized oxyhemoglobin reacts with two moles of methyl mercury iodide/mole of hemoglobin at a pH 7.5. Ingbar and Kass (119) found that normal adult hemoglobin

1. The first part of the document is a letter from the President of the United States to the Congress, dated January 1, 1861. It is a very important document, as it sets out the President's policy for the new year.

2. The second part of the document is a report from the Secretary of the Treasury, dated January 1, 1861. It is a very important document, as it sets out the Secretary's policy for the new year.

3. The third part of the document is a report from the Secretary of the Interior, dated January 1, 1861. It is a very important document, as it sets out the Secretary's policy for the new year.

4. The fourth part of the document is a report from the Secretary of the War, dated January 1, 1861. It is a very important document, as it sets out the Secretary's policy for the new year.

5. The fifth part of the document is a report from the Secretary of the Navy, dated January 1, 1861. It is a very important document, as it sets out the Secretary's policy for the new year.

6. The sixth part of the document is a report from the Secretary of the State, dated January 1, 1861. It is a very important document, as it sets out the Secretary's policy for the new year.

7. The seventh part of the document is a report from the Secretary of the War, dated January 1, 1861. It is a very important document, as it sets out the Secretary's policy for the new year.

8. The eighth part of the document is a report from the Secretary of the Navy, dated January 1, 1861. It is a very important document, as it sets out the Secretary's policy for the new year.

9. The ninth part of the document is a report from the Secretary of the State, dated January 1, 1861. It is a very important document, as it sets out the Secretary's policy for the new year.

10. The tenth part of the document is a report from the Secretary of the War, dated January 1, 1861. It is a very important document, as it sets out the Secretary's policy for the new year.

11. The eleventh part of the document is a report from the Secretary of the Navy, dated January 1, 1861. It is a very important document, as it sets out the Secretary's policy for the new year.

12. The twelfth part of the document is a report from the Secretary of the State, dated January 1, 1861. It is a very important document, as it sets out the Secretary's policy for the new year.

13. The thirteenth part of the document is a report from the Secretary of the War, dated January 1, 1861. It is a very important document, as it sets out the Secretary's policy for the new year.

has 2.0 SH groups/molecule. Riggs (120) states that a molecule of mammalian hemoglobin combines reversibly with four molecules of oxygen, one with each oxygen-combining centre or heme. These centres are all identical and are believed to be bound in the same manner to the protein, but when an oxygen molecule combines with one centre, it greatly increased the likelihood that a second oxygen will be attached to another. His investigation (120) indicates that the sulfhydryl (-SH) groups of hemoglobin are closely linked with the mechanism of heme-heme interaction in the oxygenation process. Hill and Wolvekamp (121) in 1936 found that glutathione appeared to make the oxygen equilibrium curve of a dilute hemoglobin solution slightly more highly inflected. McCarthy (122) and Hall (123) showed that foetal hemoglobin of goats and rabbits showed a greater affinity for oxygen than maternal hemoglobin. A study of the glutathione content of erythrocytes of cord blood at birth was made (see table 12). Of ten cases the glutathione content of 100 cc. of packed erythrocytes ranged from 62 to 92 mgms. with an average of 78.3 mgms. The two highest values obtained were from babies whose placenta was small and fibrotic. The foetus in utero exists in an atmosphere of low oxygen tension, and can be compared with the patient who has pulmonary disease or heart failure, in that it is difficult to oxygenate the hemoglobin. It was not possible at this time to compare the oxygen affinity of hemoglobin and the glutathione levels of erythrocytes in either the anemic patients, newborn, or in those suffering from pulmonary disease; however, it is postulated that

26.

the glutathione levels of erythrocytes maybe a factor in increasing oxygen affinity of hemoglobin.

Name	Date		GSH in mgms. %	Hem.	Mgms. GSH/100 cc. H RBC
Mr. D.M. #118420	9.3.53	Nitrogen Mustard 10 mgms. I.V. daily on Mar. 9, 10, 11 & 12.	24	39	62
	10.3.53		32.2	40	81
	11.3.53		36.8	40	92
	12.3.53		36.4	38	96
Mr. N.H. #114928	9.3.53	Nitrogen Mustard 10 mgms. I.V. daily on Mar. 9, 10, 11.	26	43	60
	11.3.53		37.6	49	77
Mr. A.D. #119564	14.4.53	Nitrogen Mustard 10 mgms. I.V. daily from April 14 - 17 th.	30	46	67
	15.4.53		28.8	46	63
	16.4.53		30.0	46	67
	18.4.53		29.6	42	71
Mr. J.E. #119826	11.3.53	Nitrogen Mustard 10 mgms. I.V. on Mar. 11, 13, 14, 15.	22.8	39	58
	17.3.53		24.4	37	66
Mrs. M.H. #119283	21.4.53	Triethylene melamine (Lederle). Apr. 21 - 2.5 mgm. Apr. 29 - 5 mgms. May 6 - 5 mgms. May 12 - 7½ mgms. May 19 - 7½ mgms.	24.8	34	73
	23.4.53		25.8	36	72
	21.5.53		27.2	39	70

Table 13 - Glutathione (Content of Erythrocytes) During Nitrogen Mustard Therapy.

Name	Time & Date	GSH in mgms. %	Hem.	Mgms. GSH/100 cc. RBC's
Mr. J.E.	Mar. 11 - Before Administration	22.8	39	58
	20 min. After "	21.6	38	57
	40 min. " "	25.2	38	66
	60 min. " "	22.4	39	57
Mr. D.M.	Mar. 10 - Before Administration	31.6	38	83
	20 min. after "	34.0	35	87
	40 min. " "	31.2	37	84
	60 min. " "	25.6	35	73
	Mar. 11 - Before Administration	28.4	37	77
	60 min. After "	31.2	35	89
	80 min. " "	30.0	34	88

Table 14 - Glutathione Content of Erythrocytes following
10 mgms. Nitrogen Mustard.

GLUTATHIONE CONTENT OF ERYTHROCYTES DURING
NITROGEN MUSTARD THERAPY

The marked reduction of glutathione content of erythrocytes in the case of Mr. J.E. (see table 10) following nitrogen mustard therapy, indicated that nitrogen mustard should be ruled out as the etiology before one could definitely state that the lowering of glutathione content of erythrocytes in this case, was due to improved pulmonary function. The ability of B.A.L. to counteract mustard gas poisoning by virtue of its free -SH groups, and the use of nitrogen mustard in bronchogenic carcinoma, also suggested the possibility that the nitrogen mustard might lower the glutathione content of blood cells and tissues.

Four cases of nitrogen mustard therapy were followed (see table 13). In no case was there a lowering of the glutathione content of erythrocytes. Two of these cases (see table 14) were followed for periods up to eighty minutes after administration of the nitrogen mustard. Again there was no marked fall in glutathione content of erythrocytes. One case of triethylene melamine therapy (see table 12) showed no marked change in glutathione content even after one month of therapy.

Nitrogen Mustard therapy therefore, does not appear to lower the glutathione content of erythrocytes.

GLUTATHIONE AND DIABETESIntroduction

Jacobs (124) in 1937 found that alloxan when given intravenously to rabbits, caused a fatal hypoglycemia with convulsions. Bailey and Bailey (125) showed that actually, alloxan caused an initial hyperglycemia, followed by hypoglycemia with convulsions and death, but if glucose were given to prevent the convulsions, there developed symptoms seen in human diabetes. They (125) and others (126 - 130, 135) showed that alloxan caused marked degeneration and death of the beta cells of the islets of Langerans. Bailey and Leech (130) showed that cataracts developed in four to six weeks in rabbits made diabetics with alloxan. Brunschwig et al (129) - 131) demonstrated that alloxan, when given to a patient with an insulin producing islet cell carcinoma, gave temporary symptomatic relief from recurrent attacks of hyperinsulism. Others (132 -133) found that alloxan would control convulsions in children due to idiopathic hypoglycemia. Goldner (134), Gomori (136) and Bailey et al (137) showed, that when the vessels to the pancreas were clamped before, and for five minutes after the injection of alloxan, the beta cells in the clamped portion of the pancreas, did not undergo necrosis, whereas, the part not clamped off showed marked changes. It has been found that the pancreatic tissue of dogs made diabetic with alloxan, contains only one quarter the insulin content of the normal pancreas (134, 138) which is similar to dogs made diabetic by partial pancreatectomy (139) by anterior pituitary extracts (140) and in human diabetes (141). The microscopic picture of other

forms of experimental diabetes e.g. pituitary diabetes (140,142, 143), that following partial pancreatectomy (144) and that following continuous glucose injections (145, 146) have been shown to be similar to those of alloxan diabetes; but with alloxan diabetes these changes occur more rapidly.

Leech and Bailey (147) reported that following the injection of alloxan the blood glutathione dropped rapidly to almost zero, and then returned to normal within 18 - 24 hours. They and others (148) reported the inability of glutathione and cysteine to protect animals against alloxan. Lazarow (149), however, in 1946 showed that the intravenous injection of large doses of glutathione or cysteine, one to two minutes prior to the injection of alloxan, caused complete protection, whereas, if given after the alloxan, only partial or no protection resulted, depending on the time interval. Palay and Lazarow (150) showed that where cysteine was used to protect rats from alloxan, there was a marked increased incidence of severe necrosis of the liver. This was explained on the possible chemical reaction between cysteine and alloxan giving dialuric acid and **cystine**; **cystine** having been shown to cause liver damage (151-153). Lazarow et al (154 -156) have shown that cysteine and alloxan give dialuric acid; and that glutathione and alloxan combine to form dialuric acid, and a substance which has an absorption spectrum giving a maximum at 305 mu. and which is thought to be an addition product of alloxan and glutathione. Bruckman and Wertheimer (157) showed dialuric acid was diabetogenic, but Archibald (158) has shown

that dialuric acid is rapidly converted to alloxan on standing in air, and their results could have been due to alloxan contamination.

Alloxan is an oxidative product of uric acid and it has been suggested that alloxan could possibly be formed during uric acid synthesis. Archibald (158) has shown that the blood of humans and dogs contained only minute amounts of alloxan (less than 0.02 mgms%). Griffiths (159) has shown that a transitory hyperglycemia could be produced in rabbits by uric acid injections; but only when they were kept on a diet deficient in methionine and cysteine, which caused a lowering of blood glutathione from 38 mgms.% to 18 - 23 mgms.%. He (160) suggests that the increased resistance of guinea pigs to alloxan as shown by Lazanow (149) and others (162) and in the common fowl *Gallus domesticus* (162) is due to their normally high blood levels of glutathione which are 58 mgms % and 60 mgms.% respectively in comparison with rabbits which are 35 - 40 mgms.%. Griffiths (160) reported guinea pigs were also susceptible to alloxan when kept on a diet deficient in methionine and cysteine, whereas, Grunert and Phillips (163) found that uric acid was non-diabetogenic in methionine and sodium deficient rats. Martinez et al (164,165, 166) observed that cysteine, thiouracil and 5-methylthiouracil given to rats for 12 to 30 days gave protection from alloxan and partial pancreatectomy and showed that protection was associated with an increased sulfhydryl concentration in liver and kidney. Methylthiouracil and propylthiouracil (167,168) thiouracil (169) and thiourea (170) have been reported to cause increased glutathione levels in blood.

Lazarow (171) showed that B.A.L. (Dimercaptopropanol) as well as cysteine and glutathione would protect animals against the development of alloxan diabetes; however, mole for mole, B.A.L. was at least twice as effective as the others. This was explained by the fact that B.A.L. contains two free -SH groups, whereas glutathione and cysteine contain only one. It is also evidence for the fact that it is the -SH group of glutathione which reacts with alloxan.

Du Vigneaud (172) has shown that insulin contains sulfur and that the sulfur was contained in a cystine molecule which is a disulfide linkage. Glutathione and cysteine (173) were found to inactivate insulin, probably by reduction of the disulfide linkage.

Glutathione-Dehydroascorbic Acid and Diabetes

Patterson (174) showed that injections of dehydroascorbic acid in rats lead to chronic hyperglycemia and glycosuria, Patterson and Lazarow (175) demonstrated protection by cysteine, glutathione and B.A.L. against dehydroascorbic acid intravenously if given before the dehydroascorbic acid, but not if given ten minutes afterwards. Banerjee (167, 177) had previously shown hypofunction of the islands of Langerhans in scorbutic guinea pigs as evidenced by diminished insulin content and degranulation of the beta cells. Banerjee and Ghosh (178) later found lowered glucose tolerance and decreased deposition of glycogen in the liver in scorbutic guinea pigs. It (179) has also been shown that there is a decreased glutathione content of the blood, adrenals, pancreas

and spleen of scorbutic guinea pigs with also the presence of dehydroascorbic acid in tissues in considerable amounts, which are normally not present. Banerjee et al (179) suggests the diminished insulin secretion in scorbutic guinea pigs, maybe due to the combined effects of low glutathione and high dehydroascorbic acid content of tissues in general and pancreas in particular.

Glutathione- Intermediary Fat Metabolism Products and Diabetes

It has long been recognized that obesity tends to increase the severity of diabetes, and with reduction in weight, diabetic patients can carry on with less insulin. Nath and Brahmachari (180) in 1944 showed that the injection of B hydroxybutyric acid, acetoacetic acid or pyruvic acid (intermediate fat metabolic products) caused elevated blood sugars and if continued for 150 days a permanent hyperglycemia ensued. They suggested that the pancreas was overstimulated by these products and became fatigued by excessive work and later showed (181, 182) that these products were responsible for partial or complete inactivation of insulin, and felt that these ketone bodies were in the long run responsible for the developement of diabetes in many cases. Nath et al (183) have also reported that acetoacetate injections in rabbits caused a marked reduction in glucose tolerance, and also in glycogen storage of liver and muscle, both of which were difficult to correct with insulin. Sodium acetoacetate injections (184, 185) have been shown to cause increased blood lactate levels and decreased ascorbic acid levels. They (186,187) have found that

in rabbits acetoacetate injections cause the blood glutathione to fall, and repeated injections brought the blood glutathione to 0 in three to five days. A single injection has been shown to cause a drop in blood glutathione reaching a low in ninety minutes, and then rising to normal within three hours. Associated with the drop in glutathione there was a marked rise in blood sugar. They have (188) recently reported that these rabbits injected with sodium acetoacetate for five weeks are much more susceptible to alloxan than normal rabbits, and found that this increased susceptibility to alloxan was associated with a marked reduction in the glutathione content of the blood.

Lazarow (149) suggests that a low beta cell glutathione content would explain the selectivity of alloxan for the beta cells. He (189) also suggests that the synthesis of insulin in physiological amounts may produce a local depletion in beta cell glutathione, and thereby render these cells more susceptible to alloxan or to other sulfhydryl inactivators which may appear in the body. Glutathione is contained almost exclusively in the intracellular fluid, and its transportation and release must be fairly slow as we have mentioned the fact that alloxan causes the blood glutathione to drop almost to zero, and following this it requires 18 - 24 hours to return to normal. Beta cell degeneration is also observed in (1) partial pancreatectomy (190), (2) massive anterior pituitary hormone therapy, (140,142,191) (3) massive glucose injections (192,193). In all these conditions the beta cells are stimulated to an increased insulin

production. Lazarow (189) further postulates that this increased insulin synthesis also sensitizes the beta cells to degeneration, because of a consequent local depletion in beta cell glutathione. As he says "If this theory of beta cell degeneration proves correct, then the glutathione metabolism of the beta cells will not only affect the etiology of alloxan and other forms of experimental diabetes, but it may also have an important bearing on the development of human diabetes".

Previous Clinical Studies of Glutathione in Relation to Diabetes

The protection by glutathione against the production of alloxan diabetes and the fact that glutathione is a normal constituent of blood cells, and all tissues have stimulated many investigations of glutathione in relation to diabetes. Camanacci (194) and Varela et al (195) in 1930, long before the discovery of glutathione protection against alloxan diabetes, reported that the glutathione content of blood was decreased in diabetes mellitis, and Camanacci stated this decrease was independent of acidosis or blood sugar changes. Dogliotti and Meloni (196) in 1935 found normal blood levels of glutathione in diabetic patients.

Recently Stock and Currence (197) studied uric acid and glutathione content of the blood in diabetes. They found there was no deviation from the normal range in either blood reduced glutathione or in blood true uric acid. Caren and Carne (198) found that fasting blood glutathione values in diabetic patients treated with insulin

and those treated by diet alone were within the normal limits 25-41 mgms.%. They found no correlation between the blood sugar level and blood glutathione. Large doses of crystalline insulin varying between 100 and 580 units in physically normal schizophrenic patients caused no change in the blood glutathione. The blood glutathione was found to be within normal limits in a case of insulin resistance requiring 520 units insulin daily, and concluded that his insulin resistance was not due to inactivation of insulin by an abnormally elevated glutathione. They concluded therefore, that their results did not support the hypothesis of a diminished glutathione content of blood being responsible for the destruction or impaired function of the beta cells of the Islets of Langerhans in diabetes. Illing and Lawrence (199) found that the concentration of total glutathione in the diabetic without ketosis, was within the normal range, but observed that diabetics with ketosis had significantly lowered concentration of total glutathione, and that the reduced glutathione paralleled the values of total glutathione. Binkley et al (200) reported that, with their method, in an unselected group of diabetic patients, the concentration of glutathione was low, but this lowered value was compensated for by an increase in the concentration of γ glutamyl-cysteine. Corrections for differences in hematocrit were not made in these studies.

Name	Age	Acidosis	Serum Cholest- erol mgms.%	Required Insulin dosage daily	Hemoglobin	Date	GSH in mgms.%	Hem.%	Mgm.GSH/100 cc. packed RBC	Comments & Associated Conditions.
1. Mr.J.D.	60	No	218	None. Diet alone	110%	3.2.53	32.8	55	59.6	Slight cardiac enlargement.
2. Mrs.S.M	57	No	313	NPH 15 units	110%	3.12.53	31.6	52	60.8	Bilateral Cataracts.
3. Mr.J.S.	32	No		NPH 30,CZ 30	90%	2.1.53	36	46	78.3	Unstable diabetes.
4. Mr.W.C.	45	No		PZ 30	102%	2.1.53	23.2	48	48.3	Previous Thyrotoxicosis. Now diabetes out of control. BMR -20 -25.
5. Mr.A.J.	54	No		PZ 50 CZ 20 in a.m. CZ 15 at noon Diet alone	104%	23.3.53	25.4	37	68.6	Furuncle and Cellulitis of neck.
6. Mr.R.B.	71	No			95%	12.3.53	34.4	45	76.4	Serum Uric Acid 9.7 Mar. 9.53
						19.3.53	28.0	39	71.8	Serum Uric Acid 7.1 Mar. 11.53
7. Mr.J.K.	86	No		Diet alone	85%	19.3.53	32.0	43	74.4	Serum Uric Acid 7.6 Mar. 19.53
8. Mrs.A.H.	64	No	247	Diet alone	97%	12.3.53	29.6	47	63	Bilateral Emphysema.
9. Mr.R.B.	22	Yes		PZ 30 units	104%	16.4.53	24.0	47	51.5	Bilateral Cataracts. Untreated Diabetes.
	Slight									
10. Mrs.R.E.	72	No		PZ 26 units	128%	13.1.53	36.8	64	57.5	Polycythemia Vera RBC 7,300,000.
11. Mr.J.M.	27	No		30 units daily	88%	10.12.53	27.8	42	66.2	Kimmelstiel Wilson Disease severe.
12. Mr.A.P.	51	Yes		NPH 50 units	77%	19.2.53	35.4	45	78.7	Kimmelstiel - Wilson Disease.
						5.3.53	29.6	42	70.5	
13. Mrs.D.H.	33	No		PZ 55 CZ 22	68%	15.1.53	23.6	32	73.8	Kimmelstiel-Wilson Disease. BUN 29.5 mgms.%. Urine 4 + protein.
14. Mr.G.S.	25	No	760	PZ 60	104%	5.12.52	23.4	47	49.8	Kimmelstiel-Wilson Disease
						3.2.53	33.2	42	79.1	
15. Mrs.L.S.	67	No		NPH 20 CZ 60	87%	19.11.52	32	43	74.3	Associated mild diabetic neuritis.
16. Mrs.A.R.	48	No		Diet alone	92%	22.1.53	34.4	48	71.6	Mild diabetes.
17. Mr.T.M.	53	No		PZ15 CZ 15 began 12.1. 53	59%	9.1.53	21.2	33	63.6	Untreated diabetes.
						12.1.53	21.6	35	62.1	Lowering of GSH in cells probably due to increased hematocrit.
						26.1.53	24.6	44	55.9	

18.	Mr. A. B.	36	No		PZ 20 units		15.1.53	24.0	45	53.3	Untreated Diabetes.
19.	Mrs. N. L.	53	No	160	Diet alone	93%	22.1.53	28.2	47	60.0	Untreated diabetes. Infected toe
20.	Mrs. E. O.	76	No		CZ 100 PZ50 b.i.d	98%	7.12.52	43.8	44	99.6	Resistant Diabetes.
21.	Mrs. E. P.	62	No		NPH 120 bid		13.1.53	33.2	46	72.2	
22.	Mrs. I. S.	40	No	181	Diet alone	66%	14.5.53	33.2	45	74	Resistant Diabetes.
23.	Mr. S. P.	20	Yes				10.3.53	34.0	38	89.5	Mild diabetes. Associated anemia. Hypertension and vaginitis.
24.	Mr. F. T.	13	No		Discharged on PZ 35 CZ 25	99%	13.3.53	48.8	48	102	Untreated acidosis. Acetone. + + +
25.	Miss E. B.	14	No		NPH 40 CZ 80	86%	12.3.53	23.2	47	50.0	Acidosis - no
26.	Mr. A. B.	64	No		Requiring 180 u. daily NPH 30	92%	26.3.53	22.4	46	48.7	Acidosis - no
27.	Mrs. H. K.	63	No				18.11.52	18.8	43	43.7	Very tall lanky boy for his age.
28.	Mr. S. J.	28	No	271			20.11.52	21.0	44	47.7	Severe juvenile diabetes.
29.	Mrs. N. C.	75	No	200			26.11.52	21.2	45	47.1	
30.	Mr. J. P.	27	No				31.3.53	25.2	48	52.5	Previous pulmonary tuberculosis. Severe juvenile diabetes.
31.	Mr. N. S.	58	No		PZ 16 units	89%	1.5.53	28.6	46	62.2	Diabetes developing during thyrotoxicosis. Thyroidectomy preformed 11.5.53
							7.5.53	21.6	42	51.4	Previously anemic.
							5.2.53	29.8	40	74.5	Anemia & Hypothyroidism.
							13.2.53	24.0	34	70.6	Anemia & Uremia
							5.2.53	28.8	32	80	Cushing's Syndrome.
							13.1.53	34.8	48	72.5	Hemochromatosis Adrenocortical Insufficiency.
							24.3.53	21.6	46	47	

Table 15 - Glutathione Content of Erythrocytes in Patients with Diabetes Mellitis.

Age	$y = a + bx$	Mgms.GSH/100 cc. RBC's
5	$53.9 + 0.2494 \times 5$	55.15
20	$53.9 + 0.2494 \times 20$	59.89
40	$53.9 + 0.2494 \times 40$	63.68
60	$53.9 + 0.2494 \times 60$	68.86
80	$53.9 + 0.2494 \times 80$	73.65

Table 16 - Statistical values of the Regression Line of mgms. Glutathione /100 cc. packed cells against Age in Cases of diabetes mellitis where y is glutathione content and x is age in years ($a = 53.9$).

RESULT OF THIS STUDY OF GLUTATHIONE IN RELATION TO DIABETES

In this study thirty one cases of diabetes mellitis were followed (see table 15). Milligrams glutathione/100 cc. packed erythrocytes varied from 43.7 to 102 mgms. A statistical study of twenty eight of these cases (3 cases No.22,29 and 31, see table 15, were omitted because of associated anemia) showed on average age of 47.2 years with an average glutathione value of 65.7 mgms./100 cc. packed erythrocytes. These cases, as the normal individual did, showed an increase of glutathione content with age (see table 16). The value of "t" is 2.32 with 26 degrees of freedom. The probability of deviation from 0 as great as that found was 0.03, which is significant at the 5% level. A comparison of table 16 and table 4 appears to show that the slope of the regression line is greater for the diabetic than the normal, but the difference is not statistically significant, "t" for the difference in the two lines being 1.263. Part of the difference in the slope of the two lines could be due to the fact that two cases of mild anemia and one case of pulmonary emphysema as associated conditions were included in this series.

In this study it should be noted there were two cases of resistant diabetes. The glutathione content of erythrocytes fell within normal limits in both cases. Two cases of severe juvenile diabetes were studied. In one case the glutathione content of the erythrocytes was below normal limits on three different occasions, while in the other case it was at the lower limits of normal.

There were four cases of diabetes mellitis with associated Kimmelstiel/Wilson's Disease, and two cases of bilateral cataracts associated with diabetes mellitis. Glutathione content of erythrocytes in these cases did not show any deviation from normal.

It appears therefore that a clinical study of diabetes mellitis in relation to glutathione content of erythrocytes does not suggest or indicate any correlation between the two. There is no suggestive evidence here to associate a low glutathione content of erythrocytes in patients with diabetes mellitis as part of the etiology of diabetes mellitis unless in juvenile diabetes. The two cases of juvenile diabetes studied here showed low glutathione levels in the erythrocytes, but more cases would have to be studied before a definite conclusion could be drawn.

The initial high value of glutathione content of erythrocytes in the case of Mr.S.P.(table 15) was probably due to ketone bodies present in blood and the method is not considered accurate for a person in diabetic acidoses (see table 3). Estimation of glutathione taken two days later, when acetone had disappeared from the urine, showed values much lower than when he was first admitted.

GLUTATHIONE LEVELS IN RELATION TO PITUITARY DISEASES

The anterior pituitary extracts have been shown to cause diabetes, (140,201 -210) which can be temporary or permanent, depending on dose, length of time of giving, and personal susceptibility, and changes in the pancreas (140,142,143,191,211,212). Atkinson (213) showed that glycosuria was found in 33% of his cases of acromegaly. Ennor (214) and Goss and Gregory (215) reported that anterior pituitary extracts and hypophyseal growth hormone respectively, caused decreased glutathione content of the liver. Conn et al (202, 206) found decreased levels of glutathione in blood associated with the development of a resistant form of diabetes, with high uric acid levels in blood and increased urinary excretion of uric acid on ACTH therapy. Hess, Kyle Doolan (205) found that ACTH caused decreased reduced glutathione levels whereas oxidized glutathione did not change. The greatest decrease of glutathione was associated with the greatest elevation of blood sugar. Kass et al (216) in a study of one patient on ACTH found diminished blood glutathione levels. Levine and Adams (207) studied ACTH therapy in Periarteritis Nodosa and found that ACTH lowered the blood glutathione levels. Ingbar et al (217) found no change in blood glutathione levels following ACTH therapy in rats. Grunert and Phillips (218) also found no changes in glutathione content of blood of rats given single and repeated injections of ACTH. Joiner (208) studied blood glutathione levels in eleven cases of ACTH therapy in humans, and found no change, even though carbohydrate intolerance developed.

Mr. M.L.

Day	Fasting Blood Sugar mgms. %	$\frac{1}{2}$ hr. Blood sugar mgms. %	1 hr. Blood sugar mgms. %	$1\frac{1}{2}$ hrs. Blood sugar mgms. %	2 hrs. Blood sugar mgms. %	$2\frac{1}{2}$ hrs. Blood sugar mgms. %	Serum Uric acid mgms. %
0	76	80	96	94	34	53	5.1
5	67	147	136	142	102	62	4.7
12	68	101	61	98	36	54	

Table 17 - Changes in Glucose Tolerance Test and Serum Uric Acid Levels as a Result of ACTH Therapy (25 mgms. I.V. daily) for 5 days.




Figure 4

Holton and Lundback (201) have reported no change in blood glutathione levels in two men receiveing ACTH even though they developed abnormal glucose tolerance curves, and lowered renal threshold to glucose. Hennaman and Altschule (219) in comparison with the others, found that ACTH given to psychotic patients caused elevation of blood reduced glutathione, two to four hours after, expressed in terms of its concentration in erythrocytes.

Conn et al (220), gave reduced glutathione intravenously to patients receiving ACTH therapy. and found that reduced glutathione caused a sharp elevation of renal threshold for glucose, and a fall in blood sugar levels which lasted for one to two hours.

In this study, four cases of ACTH therapy were followed (fig.4) The first two cases (Mr. R.S.G. and Mr.M.L.) were given ACTH for ecæma. The third case (Mr. R.B.) had pulmonary fibrosis. The fourth case (Mr. L.P.) had severe rheumatoid arthritis and had been taking cortisone 100 mgms. daily for one year, resulting in marked hypofunction of the adrenal cortex, and ACTH was given to stimulate the adrenal cortex. Mr.M.L. was the only case in which the glucose tolerance and serum uric acid levels were followed (see table 17). It will be seen he did develop an abnormal glucose tolerance although serum uric acid values did not change. It is to be noted that in all four cases there was a drop in the blood hematocrit, most marked in the first three. Associated with this drop in hematocrit there was a corresponding drop in glutathione content of blood (mgms.%), but when corrected for the change

in hematocrit the glutathione content of the erythrocytes had not changed appreciably. In the case of Mr.L.P. there ^{even}was/a marked increase in the glutathione content of erythrocytes during ACTH therapy. It should be noted that except for Henneman and Altschile (219) the others have not considered changes in hematocrit in reporting their results, and it is quite evident from the results reported here that the drop in glutathione content of blood, as reported by others, is due mostly to a state of hydremia, which developes during ACTH therapy, with a resultant drop in hematocrit. ACTH therapy does appear to lower the glutathione content of erythrocytes.

One case of pituitary insufficiency due to chromophobe adenoma of the pituitary was studied and the glutathione content of the erythrocytes was found to be within normal limits (see appendix).

GLUTATHIONE LEVELS IN RELATION TO CONDITIONS ASSOCIATED WITH
THE ADRENAL CORTEX

The adrenal cortical hormones have been shown to cause diabetes (205,221,226). Lukens et al (227) have reported a case of adrenal cortical tumor with diabetes, and Sprague et al (228) reported a case of a woman whose only manifestation of a malignant adrenal cortical tumor was diabetes, and whose diabetes disappeared on removal of the tumor. Russi et al (229) reported that diabetes occurs five times as frequently in individuals having adrenal cortical adenomas as it does in the general autopsy group. Binet and Poutonnet (230,231) reported low values of reduced and total glutathione in Addison's Disease, and found that adrenal cortical extracts or DOCA brought about a return to normal values. In comparison Hess et al (205) reported that cortisone caused a reduction in reduced glutathione, whereas oxidized glutathione did not change. Lazarow and Berman (223) showed that cortisone injected into rats caused a significant drop in blood glutathione levels. Lazarow (222-224) showed that where, either rats fed a high carbohydrate diet with the development of glycosuria, or where glycosuria developed in rats during cortisone therapy, the injection of glutathione caused an intensification of the glucosuria associated with elevated blood glucose levels. As the rats became adapted to a high carbohydrate diet, however glutathione caused only an insignificant glycosuria. Glutathione caused death to rats with severe cortisone diabetes. In comparison glutathione to normal animals in much larger doses caused no change in blood sugar or glycosuria and when given to




Figure 5

severe alloxan diabetic rats it did not increase the glycosuria. He emphasizes the fact that although glutathione may protect the beta cells of the pancreas against physiologically occurring substances, it may also have diabetogenic effects due to its action on steroids and enzyme systems. The results of Lazarow et al with glutathione in rats made diabetic with cortisone should be compared with the results of Conn et al (202,206,220), using glutathione in diabetes caused by ACTH.

Two cases of cortisone therapy were followed (see figure 5). Mrs.J.L.had multiple neurofibromatosis and Mrs.P.L. had rheumatoid arthritis. In the case of Mrs.J.L. the glutathione content of 100 cc. of packed erythrocytes fell from 76.2 mgms. to 70 mgms. which is felt to be insignificant. In the case of Mrs.PZ. there was a slight drop in glutathione content of the erythrocytes at the 5th day, but on the 7th day it had become elevated above the initial level. It should be noted again that previous investigators of cortisone therapy have failed to correct for any change in hematocrit which might occur. The results shown here do not show any marked fall in glutathione content of the erythrocytes as a result of cortisone therapy.

One case of Cushing's Syndrome was studied (see table 18). The glutathione content of red blood cells was found to be within normal limits.

Four cases of Adrenogenital Syndrome were studied (see table 18). Two of these showed values within normal limits, and two would

Disease	Name	Age	Hb.	24 hr. 17 Ketosteroids excretion (mgm.)	24 hr. corticoid excretion (mgm.)	Dehydroisoandrosterone	Glucose Tolerance	GSH in mgm. %	Hematocrit	Mgm. GSH/100 cc. packed RBC	Comments and other findings
Cushing's Syndrome	Mr. J.P.	27	90	39.7	2.12	Not Done	Abnormal	34.8	48	73	Plethoric individual with obesity of face, neck and trunk. Bluish striae of skin. B.P. 160/120. Marked osteoporosis.
Adrenogenital Syndrome	Mrs. A.E.	26	86	25.13	1.83	Neg.	Not Done	37.8	47	80	Plethoric moon face with obesity of the trunk. Purple striae over flanks. B.P. 140/110. Hirsutism.
Adrenogenital Syndrome	Mrs. J.D.	23	93	28.99	0.89	Neg.	Normal	33.8	47	72	Round hirsutic face and obese torso. B.P. 120/70.
Adrenogenital Syndrome	Master R.C.	10		17.5			Not Done	35.4	51	69	Deep voice, axillary and pubic hair. Operation showed small uterus, tubes and ovaries. Left adrenal very large.
Adrenogenital Syndrome	Baby L.W.	20 mons.						37.8 31.4	41 41	92 77	4 inches taller and 9 pounds heavier than 2 year old child.

Table 18 - Glutathione Content of Erythrocytes in Patients showing Hyperfunction of the Adrenal Cortex.

be considered high, however a later determination on L.W., age twenty months, showed that the glutathione content of erythrocytes had decreased somewhat.

One case of adrenal cortical insufficiency (see appendix) showed values within normal limits.

Even though the number of cases studied here are small it does not appear that the hormones of the adrenal cortex have any marked effect on the glutathione content of erythrocytes, as has been reported previously.

GLUTATHIONE CONTENT OF ERYTHROCYTES IN RELATION TODISEASES OF THE THYROID GLAND

Maloberti (232, 233) in 1935, found lowered glutathione blood levels in humans with hypothyroidism. Ersier(234) in 1936 showed, that in rabbits, rats and guinea pigs, the injection of thyroxine caused a decrease of 20% in total glutathione in the blood, with a 40% increase in the liver and in the heart and 30% increase in the lungs and spleen. Zunz and Vesselovsky (235) in 1938 found no change in blood glutathione levels in dogs after intravenous thyroxine injections, whereas Livierados (236) in the same year found that in dogs given 2 mgms. thyroxine/kg body weight there was a transient decrease in glutathione. He also found that thyroidectomy in dogs caused a 50 - 100% increase in blood glutathione levels. Coccialanza (237) in 1939 also reported that in dogs the blood glutathione rose following thyroidectomy. In 1943 Mutel (238) showed that the total blood glutathione decreased in proportion to the increase in the basal metabolic rate. Capra (239) in 1947 studied patients whose metabolic rate was increased with thyroxine and found that the glutathione content of blood was decreased. He (167, 168, 239) also studied the effects of methylthiouracil and propylthiouracil in normal patient and those with thyrotoxicosis and found that the blood glutathione varied inversely to the basal metabolic rate; Prina (169) reported that thiouracil given to rabbits for one month caused a moderate increase in both reduced and total glutathione content of the blood. Domingo (170) giving thiourea to patients with tuber-

Name	Age	BMR	Serum Cholesterol mgm. %	Hemoglobin	Comments and Associated Conditions	GSH mgm. %	Hem.	Mgm. GSH/100cc RBC's
Mr. N.M.	18	+29 +32	75	88%	WBC 6,950 with only 19% polymorphonuclears. See table 19.	14.8	42	35
Mr. K.S.	37	+66 +58	132	102%	Propylthiouracil 200 mgms. tid began 4 days previously	32.0	46	70
Mr. J.H.	51	+41 +43	120	96%	Radio active Iodine therapy. Second glutathione value following therapy.	22.4 26.0	40 41	56 63
Mr. E.N.	48	+43 +40	305	89%	Took Propylthiouracil 300 mgms. daily for 10 mons. Stopped 2 mons. ago because of exophthalmos. Taking iodine alone Since then had had recurrence of Thyrotoxicosis.	28.6	47	61
Miss E.C	33	+53 +53		84%	See table 20	19.6	38	51
Mrs. C.W.	44	+10 +14		92%	Clinically mild thyrotoxicosis.	27.6	41	67

Table 19 - Glutathione Content of Erythrocytes in Patients with Thyrotoxicosis.

Mr. N.M.
Age 18.

Date	BMR	GSH in mgm. %	Hem.	Mgm. GSH/100 cc. packed RBC
14.4.53	+47 +47			
15.4.53		14.8	42	35
16.4.53	+29 +32	17.2	43	40
22.4.53	+36 +33			
23.4.53		22.0	45	49
7.5.53	+24 +24	15.4	42	37

Table 20 - Glutathione Content of Erythrocytes During Tapazole Therapy for Acute Thyrotoxicosis.

Miss E.C.
Age 33

Date	BMR	GSH in mgms. %	Hem.	Mgm. GSH/100 cc. packed RBC 'C
21.1.53	-53 -53			
29.1.53		19.6	38	51
30.1.53	+33 +33	16.6	42	40
11.2.53	+29 +24			
24.2.53	+15 +12	20.0	42	48
26.2.53		22.0	42	52
10.3.53	-1 -1			
17.3.53		23.4	44	53
18.3.53		Thyroidectomy Performed.		
26.3.53		20.8	45	46
23.4.53		22.4	42	53

Table 21 - Changes in Glutathione Content of Erythrocytes During Tapazole Therapy for Acute Thyrotoxicosis.

Name	Age	BMR	Cholesterol mgm. %	Hg.	GSH mgm. %	Mgm. GSH/100cc. Hem. RBC
Mrs. E.R	47	-26 -28	315	97%	32.4	46 70
Mr. E.D.	39	-40 -42	447	66%	28.8	31 93
Mr. S.J.	28	-42 -40	271	80%	24.0	34 71

Table 22 - Glutathione Content of Erythrocytes in Patients with Hypothyroidism.

culosis and increased basal metabolic rates found that the blood glutathione content of blood increased as the basal metabolic rate decreased.

Six cases of thyrotoxicosis were studied (see table 19). The average age was 38.5 years with an average glutathione content of 57.6 mgms./100 cc. packed erythrocytes. Two of these patients were followed during therapy with tapazole. (see tables 20 and 21) The changes in glutathione content of erythrocytes did not appear to change significantly in either of these two cases, even though one case, Miss E.C. (table 21) reached a stage of euthyroidism and was followed even after thyroidectomy had been performed. It appears from the six cases that the erythrocytes of people with thyrotoxicosis contain less glutathione than normal individuals. It is interesting to note, however, that there did not appear to be any marked increase in glutathione content whereas there was clinical improvement. One case, Mr. J.H. (see table 19) who had radioactive iodine therapy in Winnipeg, and who had noticed marked personal improvement for about four days, showed an increase in glutathione content of erythrocytes from 56. to 63 mgms/100 cc. packed erythrocytes, which may or may not be significant.

Three cases of hypothyroidism were studied (see table 22). The average age was twenty-eight years with an average glutathione content of 78 mgms./100 cc. packed erythrocytes. This high average value appears to be due to the associated anemia present, especially in the case of Mr.S.J. Two of the three cases (Mr.E.D. and Mr.S.J.




Figure 6




Figure 7

were definitely myxoedematous, and Mr S.J. had suffered from diabetes mellitis. Figure 6 shows glutathione changes occurring during treatment of Mr.S.J. with dessicated thyroid. It should be noted, that, as the basal metabolic rate returned towards normal, the requirement for insulin increased, and there was a drop in serum cholesterol. Glutathione content of erythrocytes did not appear to change appreciably, and any change was inversely proportional to the change in hematocrit. Figure 7 shows the changes in glutathione content of erythrocytes in the case of Mr.E.D. It will be noted again that the glutathione content of erythrocytes appears to vary inversely proportionally to the hemoglobin and hematocrit, but with the increasing dosage of dessicated thyroid there appeared to be some lowering of the glutathione content, even though there was a decrease in hematocrit. Mention should be made however, that even though the hematocrit decreased slightly, at the end, the hemoglobin showed an increase. Whether this is a true case of hypothyroidism or whether there is some hypofunction of the pituitary gland is hard to assess. Cortin and Ketosteroid assays initially, gave values of 0.90 and 7.10 mgms./24 hours respectively. Rechecks taken six weeks later gave values of 0.46 and 6.34 mgm./24 hours. It is felt however, that if this case was primarily hypopituitary, he would have shown evidence of this on thyroid therapy. In these two cases dessicated thyroid did not appear to alter the glutathione content of erythrocytes significantly.

Name	Age	Etiology	Date	Total Serum Bilirubin mgms. %	Direct Serum Bilirubin mgms. %	Ceph. Floccul- ation in 48 hr.	Prothrombin time.	Thymol Turbidity	Comments	Date	GSH in mgms. %	Hem.	Mgms. GSH/100 cc. RBC's
Mr. N.S. Gen. Hosp. Mr. H.L.J. #50841	64	Post-trans- fusion	31.12.52 2.1.53	18.4 28.4					Semicomatose Died 16.1.53	6.1.53	23.2	43	54
	46	Post -trans- sfusion	19.10.52 22.10.52 25.10.52 30.10.52 7.11.52 14.11.52 1.12.52 15.12.52	10.5 18.8 17.2 9.34 4.6 3.13 1.65 1.13	6.6 11.8 11.6 4.77 2.46 1.76 0.81 0.43	+++ +++ ++		4.5 u 2.8 u	Associated Diabetes Mellitis	3.11.52 5.11.52 14.11.52 1.12.52 15.12.52	24.6 26.2 26.0 28.4 25.6	43 38 41 44 40	57 69 63 65 64
Miss G.P. #102820	17	Post -tra- nsfusion	3.10.52 5.12.52	11.5 0.86	8.3 0.25	+++		1.6 u	Recovered when GSH taken	5.12.52	24.2	42	58
Mr. N.S #116611	26	Infectious	29.12.52	10.3	6.47					30.12.52 2.1.53	38 40.4	56 54	68 75
Miss S.B. #106997	21	Infectious	11.12.52 18.12.52			++ ++		15 u		5.12.52 18.12.52 23.4.53	24.4 25.5 26.0	45 44 41	54 58 63
Mrs. G.S. #2320	33	Infectious	28.10.52 10.11.52 1.12.52 15.12.52	7.7 2.37 0.77 0.31	4.6 0.82 0.34 0.11	+++	24%			6.11.52 17.11.52 1.12.52 15.12.52	30.0 27.2 23.9 26.0	43 39 40 39	70 70 60 67
Mr. P.B. #114983	24	Infectious	31.10.52 4.11.52	6.13 3.60	3.35 1.97			8.2 u 4.8 u		4.11.52	24.6	46	54

Table 23 - Glutathione Content of Erythrocytes. Acute Virus Hepatitis.

GLUTATHIONE CONTENT OF ERYTHROCYTES IN RELATION
TO LIVER DISEASE

The incorporation of glycine, cysteine and glutamic acid into glutathione ((9 -15) by liver slices has stimulated investigations of glutathione in relation to the liver. Protein free diets have been shown to cause marked depletion of liver glutathione (17,241, 242), although no lowering of blood glutathione was found. Liver necrosis has been reported (17,242) on these diets, and it was felt (242) that this is probably due to some toxic agent to which the organism is more susceptible to with a reduction in liver glutathione. Brunschwig et al (243) reported that glutathione injected intraperitoneally in animals gave appreciable protection against carbon tetrachloride poisoning. Cinelli (240) reported lowered glutathione content of blood in mgms.% in obstructive liver disease. Binkley et al (80) state that the glutathione content of blood has been reported to fall in hepatectomized animals and in animals with acute hepatic disease;

Glutathione content of erythrocytes was studied in relation to acute hepatitis and other forms of liver disease. There were seven cases of acute hepatitis, (see table 23) three due to transfusions of blood or plasma, and four due to infectious hepatitis. In only one case, Mr.H.S. could one say that the glutathione content of erythrocytes was decreased. He was in a state of cholemia when the determination was made and died four days later. In the case of Miss S.B., a nurse in hospital, and who was recognized very early, there was an indication

Name	Age	Etiology	Date	HB.	Serum Protein gms. %	Albumen gms. %	Globulin gms. %	Prothrombin Time %age of normal	Total serum Bilirubin mgms. %	Direct serum Bilirubin mgms. %	Cephalin Flocculation 48 hrs.	Comments	Date	GSH mgms. %	Hem.	Mgms. GSH/100 cc. RBC's
Mrs. G.B. #103695	22	Lympho- sarcoma	25.3.53	8.2gms	6.58	3.81	2.77	8%	22.9	13		Began x-ray therapy 27.3.53	26.3.53 2.4.53 9.3.53	16.8 14 13.2	38 32 31	44 44 43
Mrs. L.G. #116128	62	Obstructive Jaundice. Tumour of Ampulla of Vater										Cholecysto- jejunostomy 16.12.52	23.12.52 2.1.53	21.6 20.2	45 41	48 49
Mrs. U. #114761	71	Liver met- astasis by adenocarcin- oma. Primary Unknown.	5.11.53		8.33	3.28	5.05		1.79	125			5.11.52	24	42	57
Mr. T. McI 10103	63	Marked Cirrhosis of the liver			8.50	3.65	4.85	52%			++		15.12.52	34.2	53	65
Mr. M.E. 106274	21	Severe Ob- structive Jaundice with biliary cirrhosis since 1950						55%	23	14.8	++	Draining bil- iary fistula attacks of chills & fever. Enlarged liver.	6.11.52	21.6	41	53
Mr. J.R. 115616	12	Cirrhosis of the liver. Etiology unknown.	17.11.52 1.12.52		6.30 6.30	1.91 1.59	4.39 4.71	29%	2.61 1.03	0.55 0.45	+++ +++	Marked Ascites	24.11.52 5.12.52	21.8 23.4	48 42	43 56

Table 24 - Glutathione Content of Erythrocytes in Liver Diseases other than of Viral Origin.

of an increase in glutathione content of erythrocytes four months later, when she had returned to work. In the other cases no definite change in glutathione content could be shown. There were six cases of liver disease other than acute hepatitis followed (see table 24). Four of the six cases showed low glutathione content of erythrocytes for their age, although one case , Mr.J.R., did later show a rise in glutathione content when there was also evidence of clinical improvement.

LEUKEMIA

Glutathione has been studied in relation to leukemias. Platt (100) reported high values of glutathione in the blood of patients with myelogenous leukemia. These values dropped to normal in whole blood following X-ray therapy. In chronic lymphatic leukemia he reported only a doubtful increase, whereas in acute lymphatic leukemia he found high values. Malenkova (244) also found higher glutathione values in patients with leukemia, and thought most of the increase was in the leucocytes. Bickel (94) ~~also~~ found a reactionary leucocytosis to 30,000 gave no appreciable change in glutathione values. Binet et al (245) found that reduced blood glutathione was consistently elevated in acute leukemia. They reported lowered values during cortisone therapy, but aminopterin, nitrogen mustard and blood transfusions did not cause this effect. Contopoulos and Anderson (246) have successfully been able to separate leucocytes from erythrocytes. In leukemias they found markedly elevated glutathione content of leucocytes, especially in acute lymphatic leukemia. X-ray therapy they found caused a decreased glutathione content of leucocytes in myelogenous leukemias. Two cases of myelogenous leukemia were studied (see table 25). The first case Mr. A.T. showed a picture of acute myelogenous leukemia and died shortly afterwards, so could not be followed. The second case, Mrs. W. Mc.D., had received a great deal of X-ray therapy, and the bone marrow and blood smear had returned to normal. It is interesting to note that even though she had a severe anemia her glutathione

Name	Age	WBC	Hg.	Hem.	GSH In Mgm. %	Mgm. GSH/100cc. RBC
Mr. A.T.	36	37,000	32%	17	31.2	184 mgm.
Mrs. N. McD	61	3,200	10%	10	5.2	52 mgm.
				14	11.9	85 mgm.

Table 25 - Glutathione Content of Blood in Myelogenous Leukaemia.

/ Date	Hb%	WBC	GSH in Mgm. %	Hem.	Mgms. GSH/100 cc. Packed RBC
24.2.53	68	76,000	37.6	31	121
26.2.53	68	77,000	36.2	36	101
3.3.53		30,000	35.4	36	98
5.3.53	68	27,000	34.8	36	97
16.4.53	83	4,100	26.8	44	61

Table 26 - Glutathione Content of Blood and Erythrocytes during x-ray therapy in a Case of Chronic Lymphatic Leukaemia.

content was below the normal limits for her age, and the second determination, which was taken two days later, during which time she had received two blood transfusions, was much higher. This could either be due to an error in the method, as at this level (5.2 mgms.%) the accuracy of the method is to be questioned, or this could be due to receiving normal erythrocytes by transfusion which had not received X-ray therapy, which could take up or manufacture their own glutathione. One must realize that we are measuring erythrocytes and leucocytes together, and not differentiating between the two; but the case of acute myelogenous leukemia did show very high values.

One case of chronic lymphatic leukemia (see table 26) showed high levels of glutathione. It is interesting to note that even though there was a drop in white blood count with X-ray therapy from 77,000 to 27,000 there was not a significant change in glutathione content, but later, with an increase in hemoglobin and hematocrit, there was a marked decrease in glutathione content. It must be realized that we are again not separating the leucocytes from the erythrocytes, but when there was no marked fall in glutathione content initially with a marked fall in leucocyte count, the marked fall in glutathione content can probably be ascribed to the elevation in hematocrit and hemoglobin.

Any worthwhile study of glutathione in relation to leukemia would require a separation of the leucocytes from the erythrocytes, as Contopoulos and Anderson (246) have accomplished, and then a measure of glutathione content of each separately.

Name	Ethiology & Comments	WBC	PMN%	Lymph %	Hg.	Date	GSH mgms. %	Hem.	Mgm. GSH/100cc RBC
Mr. J.S.	Infectious Mononucleosis. Temp 101 degrees, age 20	21,050	37%	61%	103%	13.2.53 17.2.53 17.3.53	30.4 34 33	49 51 50	62 66 64
Mr. A.R.	Measles. Temp. 104 degrees, Age 22.	5,400	84%	16%	104%	8.4.53	28.2	42	67
Miss L.J.	Subdiaphragmatic Abscess. Temp. 102 degrees. Sed. Rate 41, age 21.	7,050	58%	42%	75%	3.2.53	26.8	35	77

Table 27 - Glutathione Content of Erythrocytes in Patients with Acute Pyrexia.

Name	Age	Associated Conditions	ESR	Hg.	GSHmgms %	Hem.	Mgm.GSH/100 cc. RBC's packed
Mrs. P.Z.	75	Rheumatoid Arthritis.	35	73%	24.2	37	65
Mr. P.G.	50	Chronic Osteomyelitis.	44	96%	36	43	84
Mr. J.W.	22	Probably subacute Bacterial Endocarditis.	38	84	21.2	36	59
Miss M.Ø.	7	Behaviour Problem	26	80%	34.4	37	93
Mr. C.McC	30	Recurrent Diarrhoea. Arthritis.	37	70%	39.6	36	110
		is. Erythema Multiforme.		89%	35.6	42	85
Miss L.W.	22	Acute Rheumatic Fever	40	84%	26.0	35	74
Mrs. E.R.	53	Erythema. Nodosum	53	92%	27.2	37	73
Mr.D.D.	60	Rheumatoid Arthritis	45	92%	38.4	46	84
Miss L.J.	21	Subdiaphragmatic Abscess	41	75%	26.8	35	77
Mr. L.P.	39	Rheumatoid Arthritis.	44	40%	40.0	31	129

Table 28 - Glutathione Content of Erythrocytes in Diseases Associated with Elevated Erythrocyte Sedimentation Rates.

PYREXIA

Three cases of pyrexia were studied (see table 27). It will be noted that all glutathione values were within normal limits, except possibly in the case of Miss L.J., who was probably high for her age. It should be noted however, that her hematocrit was low. The glutathione content of erythrocytes in the case of Mr.J.S., taken one month later after he had recovered, showed no appreciable change from when he had a high temperature.

ACTIVE ERYTHROCYTE SEDIMENTATION RATES

Ten patients were studied who had high erythrocytes sedimentation rates (see table 28). The average age was thirty-eight years, and the average glutathione content of erythrocytes was 85 mgms. It should be noted that in only one case was the patient definitely anemic. It is interesting to note that six of these cases belonged to the group of collagen diseases. It would appear therefore that conditions associated with elevated sedimentation rates are also associated often with elevated erythrocyte levels of glutathione.

PREGNANCY

Four cases of pregnancy were studied (see table 29). Of these it was only possible to follow three after delivery. Of the four cases studied, two showed high values of glutathione during pregnancy for their age. It is interesting to note that all three cases followed after delivery showed elevated glutathione values

Name	Age	Date due to be delivered	Date of Delivery	Hg.%	Date of GSH Determination	GSH in mgm.%	Hem.	Mgm.GSH/100 cc. RBC's
Mrs. G.P.	32	Late in February		78%	12.12.52	24.4	38	64
Mrs. R.S.	18	End in Dec - ember	23.12.52	80%	8.12.52 20.1.53 20.2.53	30.0 31.6 39.6	38 45 45	79 70 88
Mrs. A.I.	24	2.2.53	5.2.53		8.12.53 20.1.53 3.2.53 19.2.53 17.3.53	29.7 24.0 28.8 35.0 45.0	36 39 40 48 46	73 62 72 73 98
Mrs. R.S.	18	28.1.53	23.1.53	82%	15.1.53 27.1.53 26.3.53	32.8 33.6 40.4	39 40 44	84 84 92

Table 29 - Glutathione Content of Erythrocytes During and Following Pregnancy.

within two months of delivery. The significance of this finding is not clear. In each case there was an increase in hematocrit following delivery, when it might be expected that glutathione values would fall instead of rising.

MISCELLANEOUS CONDITIONS STUDIED

It was suggested, because of the results found in pulmonary disease, that a rise in glutathione content following lobectomy could be expected. One case was followed (see table 30). Unfortunately the patient developed a haemopneumothorax following left lower lobe lobectomy (for bronchiectasis), and as will be seen developed a marked drop in hematocrit. The changes in glutathione content of erythrocytes however, do vary inversely to the change in hematocrit.

Date	GSH in Mgms. %	Hematocrit	GSH/100cc. packed RBC
20.4.53	25.0	40	63
22.4.53	31.2	31	101
27.4.53	25.2	37	68

Table 30. Glutathione content of Erythrocytes in one case before and after Lobectomy.

One case of renal glycosuria was studied. Blood specimens for glucose taken during the day were within normal limits. The blood glutathione was 33.6 mgms. % with a hematocrit of 47% giving 72 mgms. glutathione /100 cc. packed erythrocytes, which is within normal limits.

Denny-Brown and Porter (247) reported normal blood levels of glutathione in two cases of Wilson's Disease, both before and after receiving B.A.L. (2-3 dimercaptopropanol). One case was followed in this study (see table 32), and he showed consistently low glutathione content of erythrocytes. Liver function tests in this case were all normal. Courses of B.A.L. were given for ten days in November 1952,

and beginning January 6th.1953, and again beginning February 10th. 1953. During the last course, on the third day, he developed a severe reaction and so B.A.L. was stopped and he was restarted on a small dose of B.A.L. on February 16th.1953. There had been clinical improvement in this case with B.A.L. therapy. The association of copper with the oxidation of glutathione (21,46) and the fact that B.A.L. contains two free -SH groups makes this an interesting finding.

date	GSH in Mgms.%	Hem.	Mgm.GSH/100 cc. packed Erythrocytes
21.11.52	23	50	46
6. 1.53	24.4	52	47
13. 1.53	23.6	46	51
15. 1.53	20.8	48	43
10. 2.53	25.2	48	53
17. 2.53	20.4	45	45

Table 31 - Glutathione Levels in a case of Wilson's Disease during BAL Therapy.

One case of hemochromatosis (see appendix) with diabetes, adrenocortical insufficiency and probable liver involvement was studied. The glutathione content of erythrocytes was 47 mgm/100cc. packed erythrocytes which is quite low for a man fifty-eight years of age

One case of delayed puberty, a boy of twelve years (see appendix) showing obesity, hypothyroidism and hypogonadism, had a glutathione content of 62 mgms/100 cc. packed erythrocytes.

One case of non-tropical sprue, a woman aged fifty, had a glutathione content of 72 mgm./100 cc.packed erythrocytes. In this case there was fifteen to twenty pounds weight loss in one year with low serum proteins (total 4.68 gms% with Alb.2.90 and Glob. 1.78).

One case of acute intermittent porphyrinuria, a woman, (see appendix) twenty years old, had a glutathione content of 60 mgms./100 cc. packed erythrocytes.

Two cases of gout were studied (see appendix). The first was a man, forty-one years of age, with a serum uric acid of 7.2 mgms.%. His glutathione content was 67 mgms./100 cc. packed erythrocytes. The second case was a man, age seventy-one, with unrecognized diabetes mellitis, whose serum uric acid was 9.7 mgms%. His glutathione content was 76 mgm/100 cc. packed erythrocytes.

One case of hypercholesterolemia, a woman (see appendix) aged thirty-three, with coronary insufficiency was studied. Her serum cholesterol was 396 mgms.% and the glutathione content was 68 mgms./100 cc. packed erythrocytes.

One case of idiopathic hypocalcemia, a woman, (see appendix) age seventy-two showed a glutathione content of 59 mgm/100 cc. packed erythrocytes. It is to be noted that at this time she was quite anemic, (hematocrit 30%), and with her age, one would have expected a much higher glutathione content.

A woman who showed marked improvement on pellets of DOCA implanted and whose urinary ketosteroids and cortin levels of excretion were within normal limits, showed a glutathione content of 49 mgm./100 cc. packed erythrocytes. Grunert and Phillips (248) found lowered glutathione levels in potassium, chloride, sodium, and potassium, and sodium chloride deficient rats. They found also that DOCA temporarily reversed the effect of sodium deficiency. They

(249) were also able to show that DOCA exerted some protection against alloxan, and that sodium deficient rats were more susceptible to alloxan. It is interesting that Zwemer et al (250,251) found the potassium tolerance of rats and mice was greatly increased by glutathione, but felt that the glutathione caused a toxic reaction with adrenal cortical stimulation, and that this was the mechanism of protection. It would be of value to study glutathione content of erythrocytes more extensively in patients with marked electrolyte imbalances.

One case of epilepsy, grand mal type, a man aged twenty-seven years showed a glutathione content of 74 mgms./100 cc. erythrocytes, which is at the high limits of normal for his age.

Three cases of atopic dermatitis were studied (see table 32). Two of the three cases showed values within normal limits. The other case, it should be noted had an elevated sedimentation rate which might account for the high value obtained.

Name	Age	Erythrocyte Sed. Rate	GSH in Mgms. %	Hem.	Mgm. GSH/100cc. Packed RBC
Mr. R. S. G.	24	2	29.6	51	58
Mr. M. L.	69	8	32.4	49	66
Mr. L. B.	58	18	38.2	45	85

Table 32 - Glutathione content of Erythrocytes in Patients with Atopic Dermatitis.

DISCUSSION OF RESULTS

1. Normal Values

From the results found, there is a slight but significant increase in glutathione content of erythrocytes with increasing age. This maybe due to decreased efficiency of cardiac and pilmonary function in the older age group. It was difficult to pick what would be considered normal individuals in this age group., especially from the patients in hospital.

2. Conditions Associated with poor oxygen carrying capacity of the blood

In patients with anemia, pulmonary or heart disease, and in the cord blood of newborn babies, an increased glutathione content was found. In all these cases there is a deficiency of oxygen carrying capacity of the blood, either because of a deficiency of hemoglobin, or because of difficulty in the hemoglobin becoming oxidized. The finding of increased affinity of foetal hemoglobin over maternal hemoglobin, and the fact that foetal erythrocytes contain more glutathione than normal erythrocytes, suggests that possibly the elevated glutathione content of erythrocytes in those conditions maybe a factor in oxygen transportation to and from hemoglobin. It is suggested that this would be a worthwhile study at a future date.

3. Nitrgen Mustard Therapy

Nitrgen Mustard therapy does not appear to lower the glutathione content of erythrocytes.

THEORY

1. Introduction

The first part of the book is devoted to the study of the

theory of the differential equations of the second order.

The second part of the book is devoted to the study of the

theory of the differential equations of the third order.

The third part of the book is devoted to the study of the

theory of the differential equations of the fourth order.

2. The theory of the differential equations of the second order

The first part of this chapter is devoted to the study of the

theory of the differential equations of the second order.

The second part of this chapter is devoted to the study of the

theory of the differential equations of the second order.

The third part of this chapter is devoted to the study of the

theory of the differential equations of the second order.

The fourth part of this chapter is devoted to the study of the

theory of the differential equations of the second order.

The fifth part of this chapter is devoted to the study of the

theory of the differential equations of the second order.

The sixth part of this chapter is devoted to the study of the

3. The theory of the differential equations of the third order

The first part of this chapter is devoted to the study of the

theory of the differential equations of the third order.

4. Diabetes Mellitis

The glutathione content of erythrocytes in cases of diabetes mellitis does not appear to vary significantly from the normal values obtained, unless in the case of the severe juvenile diabetics, and a larger series would have to be obtained before one could state there was a significant lowering of glutathione content of erythrocytes in the group. The method of glutathione estimation used is not considered accurate for patients in diabetic acidosis.

5. Anterior Pituitary Gland

ACTH does not appear to cause a drop in glutathione content of erythrocytes as has been suggested before. The drop in glutathione content of whole blood, as we found, was due to a lowering of the hematocrit, probably due to water retention and a resulting hydremia.

In one case of pituitary insufficiency the glutathione content erythrocytes was found to be within normal limits.

6. Adrenal Cortex

Cortisone does not appear to change the glutathione content of erythrocytes as again, has been suggested before. Hyperfunction of the adrenal cortex, both in Cushing's Syndrome and in the Adrenogenital-Syndrome showed normal values. One case of adrenal cortical insufficiency also showed values within normal limits.

7. Thyroid Gland

In acute thyrotoxicosis there appears to be a lowered glutathione content of erythrocytes, but there did not appear to be any increase in glutathione content during tapazole therapy or following

thyroidectomy.

In hypothyroidism there does not appear to be any marked change in glutathione content of erythrocytes unless there is an associated anemia. Thyroid therapy does not appear to alter the glutathione content of erythrocytes.

8. Liver Disease

Acute infectious hepatitis does not appear to lower the glutathione content of erythrocytes unless in the fatal cases where the patient is in cholemia. In cases of severe hepatic insufficiency, other than of infectious origin, there appear to be a lowering of glutathione content of erythrocytes. The glutathione content of erythrocytes does not appear to have any value as a diagnostic aid in hepatic disease, or in assessing hepatic function.

9. Leukemia

Any worthwhile study of glutathione in relation to leukemia would require a separation of the leucocytes from the erythrocytes which was not done here.

10. Pyrexia

Pyrexia does not appear to alter the glutathione content of erythrocytes.

11. High Erythrocyte Sedimentation Rates

Patients with high erythrocyte sedimentation rates appear to have elevated glutathione content of erythrocytes. The significance of this finding is not clear, and might be worth further investigation.

12. Wilson's Disease (Hepatolenticular Degeneration)

One case of Wilson's Disease showed lowered glutathione content of erythrocytes. The association of copper with the oxidation of glutathione (21,46) and the fact that B.A.L. contains two free -SH groups makes this an interesting finding.

13. Abnormalities in Electrolytes

The findings of low glutathione content of erythrocytes in a case of idiopathic hypocalcemia, and one case of DOCA deficiency suggests that a more extensive study of patients with marked electrolyte imbalances might be worthwhile.

14. Pregnancy

Elevated glutathione content of erythrocytes following pregnancy were found, even with an increased hematocrit, the significance of which is not clear.

SUMMARY

1. The historical background of glutathione, its discovery, the previous basic investigations of its formation and function, and the previous clinical studies are described.
2. The methods for its determination are described.
3. The results obtained from many patients with a variety of diseases are presented.
4. The significance and possible explanation of some of the results observed are discussed.
5. Probable lines of future investigation are indicated.

APPENDIX

BINKLEY ET AL'S METHOD FOR DETERMINATION OF GLUTATHIONE
AS DESCRIBED IN THE JOURNAL OF BIOLOGICAL CHEMISTRY
VOLUME 188, 159 - 162, 1950

Whole blood was collected with heparin as the anticoagulant, (oxalate was found to be unsatisfactory) and a hematocrit was determined; 5 ml. of the whole blood were transferred to an Erlenmeyer flask and 10 ml. of water, saturated with digitonin, were added. After hemolysis was complete 2 ml. of 50 per cent trichloroacetic acid were added dropwise with mixing. The flask was stoppered, shaken vigorously, and the mixture was centrifuged until a clear supernatant solution was obtained. 5 ml. portions of the supernatant solution were transferred to each of two colorimeter tubes (calibrated at 7 ml.) and 1 ml. of 2 M phosphoric acid was added to each tube. One tube was heated in a boiling water bath for 90 minutes, and after cooling 1 ml. of 6 N sodium hydroxide was added to each tube. The volume was adjusted to 7 ml. and the method of Sullivan and Hess (9) was applied. The tubes were read (5 minutes after the addition of hydrosulfite) at 500, 540 and 580 mu. in the Coleman junior clinical spectrophotometer.

Calculation of Results - As has been reported, the reading at 540 is a measure of total cysteine and cysteinylglycine. The ratio between the readings at 500 and 580 mu. is a measure of the relative concentrations of cysteine and cysteinylglycine. The 500:580 ratio for cysteine was found to be 3.4; the ratio for cysteinylglycine was 1.3. The composition of each was calculated from a graph utilizing these two values. Since all values were expressed as mg. per cent of

glutathione, the standard curve was determined with solutions of glutathione. The values that were obtained were total glutathione (the 540 value of the heated tube), per cent cysteine in the heated tube (from the 500:580 ratio), cysteinylglycine plus cysteine (as glutathione) in the unheated tube, and the per cent cysteine in the unheated tube. From these values the concentration of cysteinylglycine, cysteine, glutathione, and γ -glutamylcysteine was calculated. Since no free cysteine was detected in the amount of blood used in these determinations (i.e. the ratio on the unheated tube was 1.3) only the values for cysteinylglycine, γ -glutamylcysteine, and glutathione are reported. In practice all values are corrected to a hematocrit of 50 per cent.

METHOD OF SULLIVAN AND HESS (9) FOR DETERMINING
CYSTINE IN URINE

To 10 cc. of urine add 4 cc. of 5 per cent NaCN in N NaOH, stir, centrifuge. When ten minutes have elapsed from the time of adding the cyanide, take 7 cc. of the supernatant liquid for colorimetric determination.

To 7 cc. add 2 cc. of 1 per cent 1,2 -Naphthoquinone-4-sodium sulfonate, shake for ten seconds, add 5 cc of 10 per cent anhydrous Na₂SO₃ in 0.5N NaOH, and wait thirty minutes. Then add 2 cc. of 5N NaOH, shake, add 1 cc. of 2 per cent Na₂S₂O₄ in 0.5N NaOH.

Match against 5 cc. of an appropriate cystine standard plus 2 cc. of alkaline sodium cyanide and treat as in the above colorimetric work.

MIMEOGRAPHED COPY OF THE METHOD AS RECEIVED FROM DR. BINKLEYESTIMATION OF GLUTATHIONEREAGENTS AND MATERIALS

Heparin Bottles - Add 1.0 cc. of a heparin solution containing 3.0 mg. of heparin per cc, to used penicillin bottles. The bottles are dried in a low temperature vacuum oven, cooled and stoppered with rubber stoppers.

Digitonin Water - 1 gram of digitonin is dissolved in 2 litres of distilled water and the solution is filtered.

50% Trichloroacetic acid - 500 cc. of water is added to 500 grams of TCA.

2M H_3PO_4 - 68.5 cc. of 85% H_3PO_4 (14.6M) is diluted with water to a volume of 500.

6 N NaOH - 100 cc. of 50% NaOH (19.0 N) is added slowly to 200 cc. of water.

SULLIVAN -HESS REAGENTS :

5% NaCN in 1 N NaOH - 100 grams NaCN is dissolved in 2 litres of

1 N NaOH (111.1 of 50% NaOH plus water to make 2 litres).

2% Sodium B-naphthoquinone 4-sulfonate - (made up fresh every day).

20 mgm. of the color reagent /cc. of H_2O .

10% Na_2SO_3 in 0.5N NaOH - 200 grams of Na_2SO_3 dissolved in 2 litres of 0.5N NaOH (55.5 cc, 50% NaOH added to water to a volume of 2 litres)

1% Na_2SO_4 in 0.5N NaOH -(made up fresh just before use). 10 mgm.

$Na_2S_2O_4$ per cc. of 0.5N NaOH (27.7 cc 50% NaOH added to water to a volume of 1 litre).

PROCEDURE :

The heparinized blood is well mixed and 5 cc. is drawn off accurately with a volumetric pipet into a 50 cc. Erlenmeyer flask. 10 cc. of digitonin water is added and the solution is well mixed and allowed to stand for five minutes. 2 cc. of 50% TCA is added, the flask immediately stoppered with a rubber stopper and the contents mixed vigorously. After mixing well, the contents of the flask are transferred to a centrifuge tube and centrifuged until a clear filtrate is obtained. To obtain a clear filtrate free from precipitate, the filtrate is generally transferred to a second tube and centrifuged again. Two 5 ml samples of the clear filtrate are transferred to colorimetric tubes calibrated to 7 cc. 1 ml. of 2M H_3PO_4 is added to each of the tubes and the solutions are well mixed. One tube is placed in a boiling water bath for 90 minutes. After heating, the tube is cooled by immersion in cold water. 1 ml. of 6 N NaOH is then added to each tube. The volume in the heated tube is corrected to 7.0 with water.

SULLIVAN-HESS DETERMINATION

2 cc. of 5% NaCN in 1 N NaOH is added to all the tubes. The tubes are shaken and allowed to stand for ten minutes. Then 1 cc. of the color reagent is added to the first tube and the tube is shaken vigorously for 30 seconds. 1 cc. of the color reagent is then added to the second tube which is then similarly shaken. Then 5 cc. of 10% Na_2SO_3 in 0.5N NaOH is added to the first tube and the contents are

thoroughly mixed by shaking the tube five times. Color reagent is then added to the third tube and shaken thirty times. 5 cc. of 10% Na_2SO_3 is then added to the second tube and so on (when shaking the tubes, the tubes are flipped from the wrist),

The tubes are allowed to stand for thirty minutes. When more than 10 or 11 tubes are involved, the Sullivan test is run on a staggered series of no more than 10 tubes in one series.

The tubes are well shaken and 2 cc. of 1% Sodium hydrosulfite in 0.5N NaOH is added to each. The tubes are again well shaken and are read in the colorimeter 5 minutes after the hydrosulfite has been added. It has been found that when the tubes have been well shaken throughout the entire procedure, the colorimeter readings remain constant for about twenty minutes after the addition of Na hydrosulfite.

o/o Transmission of the tubes is read at 540 m μ . The optical density of the heated tubes are read at 500 and 580 m μ .

with
A blank tube is run/ every series and contains : 2cc. H_2O , 2.5 cc. digitonin H_2O , 0.5 cc. 50% TCA, 1.0 cc. 2 M H_3PO_4 1.0 cc. 6 N NaOH.

GLUTATHIONE STANDARDS:

A solution containing 1 mg. GSH/cc. or 0.5 mg. GSH/cc. is made up in a volumetric flask. In the usual series, one will have a blank tube and tubes containing 0.2 mg., 0.75 mg. and 1.0 mg. GSH. The volume in all the tubes is made up to 2cc. with water. 2.5 cc. of digitonin solution is added to each tube followed by 0.5 cc. 50% TCA and 1.0 cc. of 2M H_3PO_4 . The tubes are shaken after the addition of each reagent and all the tubes with the exception of the blank are put in a boiling

water bath for ninety minutes. As outlined in the procedure the tubes are cooled, neutralized with 6N NaOH and made up to a volume of 7.0cc. with water. A Sullivan-Hess test is run. Colorimetric readings of the tubes are made at 540 mu. It has been found that 0.5 mg. GSH will give a reading of from 53 to 56%.

A standard chart is set up such that mgm. o/o GSH reading may be made directly.

A correction for the dilution of blood is made as follows :

$$\frac{5\text{cc. blood used}}{17\text{ cc. total filtrate}} = 0.294\text{ cc. blood/cc}$$

$$\frac{5\text{ cc.} \times 0.294\text{ cc. blood/cc}}{\text{blood / 5 cc. filtrate}} = 1.47\text{ ml.}$$

$$x\text{ mgm. GSH} \times \frac{100}{1.47} = \text{mgm. o/o GSH}$$

The mgm. o/o GSH is plotted against o/o Transmission on a 1 cycle semi-log graph paper.

Cysteinylglycine is read in the unheated tube at 540 mu.

GSH is read in the heated tube minus the reading of the cysteinylglycine.

A total GSH is that reading obtained in the heated tube alone.

The percentage of glutamylcysteine is obtained from the ratio of the density at 500 to that at 580. The 500/580 ratio for cysteine and for hydrolyzed glutathione (cysteinylglycine) should be determined for the individual colorimeter. Our values have been found to be 1.3 for cysteine and 3.6 for cysteinylglycine. Per cent cysteine (or glutamylcysteine) is a straight line relationship so that at a ratio of 1.3 the percentage is zero and at 3.6 the percentage is 100.

THE NITROPRUSSIDE METHOD FOR THE DETERMINATION OF BLOOD GLUTATHIONE
by
Thompson, R.H.S. and Watson, D., J. Clin Path. 5, 25 -29, 1952

Reagents

- (1). 10% (W/V) trichloroacetic acid (AR).
- (2). Ammonium sulphate, solid (AR).
- (3). Ammonium sulphate, saturated aqueous solution.
- (4). M-sodium nitroprusside (AR), 0.05 in saturated ammonium sulphate. (AR)
- (5). 8N Ammonium hydroxide (AR)
- (6). Standard glutathione (B.D.H.) solution 1 mg./ml. This solution must be freshly prepared for each estimation.

Method

0.5 ml of freshly drawn blood (oxalated or heparinized) is added to 1.5 ml. of glass distilled water in a 15 ml. centrifuge tube, and allowed to stand for five minutes to settle. Then 2 ml. of 10% trichloroacetic acid are added, and the mixture well stirred with a glass rod and allowed to stand for five minutes, after which it is centrifuged for five minutes, at 3,000 r.p.m. Then 2 ml. of the clear protein-free supernatant are pipetted into a stoppered 10 ml. graduated cylinder. Solid ammonium sulphate is added to saturate the solution (by tipping in 1.4 g. contained in a marked tube); after shaking the volume is adjusted up to 3 ml. with saturated ammonium sulphate.

For the production of color 0.5 ml. of 0.05 M-nitroprusside reagent is added, followed by 0.7 ml. of 8N ammonium hydroxide.

After transferring into cells of 1 cm. optical depth the color

... ..
... ..

...

... ..

... ..

... ..

... ..

... ..

... ..

... ..

...

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

... ..

intensity is read in a photoelectric colorimeter 30 seconds after the addition of the ammonium hydroxide, using an Ilford spectrum green (604) filter. A reagent blank determination is carried out using 1 ml. water and 1 ml. 10% trichloroacetic acid, with all subsequent additions as for the blood filtrate. All tubes are compared against water.

Standards

The standard glutathione solution is diluted tenfold to give a solution containing 100 μg GSH/ml. To prepare a standard curve 0.2, 0.4.....1.0 ml. samples (i.e. 20, 40, . .100 μg . GSH) are each diluted with water to 1.0 ml. The 1.0 ml. of 10% trichloroacetic acid is added to each, and the estimation carried out as for the blood filtrates. One standard tube (containing 60 or 80 μg . GSH) is included in each series of blood estimations.

Normal Glutathione Content of Erythrocytes

	Age	Condition	GSH in mgm.%	Hem.	Mgm.GSH/100 cc. Packed RBC
1.	5	Poliomyelitis recovering	21.6	38	57
2.	8	Poliomyelitis recovering	28.8	43	67
3.	8	Poliomyelitis recovering	28.4	42	68
4.	8	Poliomyelitis recovering	31.6	48	66
5.	12	Osteogenesis Imperfecta	26.6	45	59
6.	12	Healed burns	26.3	38	69
7.	12	Poliomyelitis, recovering	24.8	45	55
8.	12	Poliomyelitis, recovering	24.2	41	59
9.	14	Poliomyelitis, recovering	24.4	46	53
10.	16	Congenital Hip	30.6	45	68
11.	17	Poliomyelitis, recovering	29.0	53	55
12.	19	Poliomyelitis, recovering	24.4	41	60
13.	19	Poliomyelitis, recovering	24.4	46	53
14.	19	Poliomyelitis, recovering	25.5	50	51
15.	21	Poliomyelitis, recovering	27.0	46	59
16.	21	Poliomyelitis, recovering	28.8	53	54
17.	21	Poliomyelitis, recovering	28.2	44	64
18.	22	Previous Fractures	35.4	52	68
19.	23	Poliomyelitis	26	41	63
20.	23	None	30.4	49	62
21.	26	None	36.8	52	71
22.	27	Injured Rectum	33.1	49	68
23.	28	Poliomyelitis, recovering	28.0	44	64
24.	29	Poliomyelitis, recovering	26.1	45	58
25.	30	Poliomyelitis, recovering	24.6	47	52
26.	32	Poliomyelitis, recovering	33	43	77
27.	32	None	27.6	46	60
28.	35	Poliomyelitis, recovering	22.8	44	52
29.	37	Poliomyelitis, recovering	31.5	45	70
30.	39	Poliomyelitis, recovering	29.8	42	71
31.	41	Back Strain	30.0	44	67
32.	44	Spinal Fusion	34.4	47	73
33.	47	Healed Fracture	30.2	46	66
34.	47	Meniscectomy	29.6	39	76
35.	47	Intravertebral Disc	36.8	45	81
36.	50	Healed Fracture	30	53	57
37.	53	Healed Fracture	32.8	49	67
38.	57	Painful back	24.0	39	62
39.	57	Osteoarthritis	24.8	44	56
40.	63	Injured Hip	30.4	49	62
41.	63	Previous Jundet Operation	23.2	37	63
42.	63	Osteoarthritis	30.5	50	61
43.	64	Osteoarthritis	32.8	50	66
44.	68	None	35.2	46	77
45.	68	Healed fractures	29.5	44	67
46.	69	Osteoarthritis	33.2	44	76
47.	69	Osteoarthritis	34.3	52	66
48.	72	Healed Fracture	26.8	41	65
49.	73	Osteoarthritis	21.6	36	60
50.	77	Healed Fractures	33.2	50	66
51.	80	Healed Fractures	38	53	72

APPENDICES

Glutathione Content of Erythrocytes in Conditions Not Shown in the Tables

Disease	Name	Age	GSH in Mgm. %	Hem.	Mgm. GSH/100 cc. RBC	Comments
Adrenal Cortical Insufficiency.	Mrs. A. J.	23	29.2	43	68	
Hemochromatosis	Mr. N. S.	58	21.6	46	47	Associated Diabetes Mellitis, Adrenal Cortical Insufficiency, and probably some liver involvement.
Delayed Puberty	Mr. N. O.	12	31.2	50	62	High pitched voice. Genitalia undeveloped. BMR -16 -21.
Acute Inter- mittent Porphy- ria	Mrs. C. C.	20	27	45	60	
Non-Tropical Sprue	Mrs. H. W.	50	32.4	45	72	Marked weight loss. Low serum protein. (Total 4.68 gm. %).
Gout	Mr. R. B.	71	34.4	45	76	Unrecognized Diabetes. Serum Uric Acid 9.7 mgm. %
Gout	Mr. M. W.	41	24	36	67	Serum Uric Acid 7.2 mgm. %
Hypercholest- erolemia	Mrs. D. M.	33	27	40	68	Serum Cholesterol 390 mgm. % BMR -13 -18.
Idiopathic Hypocalcemia	Mrs. V. A.	72	17.8	30	59	Also suffering from anemia.
Possible DGA Deficiency	Mr. M. B.	39	21	42	49	
Epilepsy /Grand Mal	Mr. M. D.	27	34.6	47	74	
Hypopituitarism	Mrs. V. S.	58	32.1	45	71	Chromophobe Adenoma of the Pituitary.

BIBLIOGRAPHY

BIBLIOGRAPHY

1. Hopkins F.G.: XXXII On An Autoxidisable Constituent of the Cell, *Biochem. J.* 15: 286 - 305, 1921
2. Hunter, G. and Eagles, B.A.: Glutathione; A Critical Study, *J. Biol. Chem.*, 72: 147 - 166, 1927
3. Hopkins, F.G.: On Glutathione; A Reinvestigation, *J. Biol. Chem.* 84: 269 - 320, 1929.
4. Kendal, E.C.: McKenzie, B.F. and Mason, H.L.: A study of Glutathione. I. Its Preparation in Crystalline form and its Identification, *J. Biol. Chem.* 84, 657 - 674, 1929.
5. Bellows, J.G.: Cataract and Anomalies of the Lens, Page 164: C.V. Mosley Company, St. Louis, 1944.
6. Bellows J.G., and Shoch D.E.: Alloxan Diabetes and the Lens. *American Journal of Ophth.*, 33: 1555 - 1564, 1950.
7. Bellows J.G.: Biochemistry of the Lens. Influence of Vitamin C and Sulfhydryls on the Production of Galactose Cataract. *Arch Ophthalmol.* 16: 762 - 769, 1936.
8. Fridman, A.P.: The Comparative Determination of Vitamin C and Glutathione in the Cerebrospinal fluid, *Arch. Sci. Biol.* (U.S.S.R.) 40: 117 - 120, 1936, *C.A.* 31: 6714, 1.
9. Waelsch H., and Rittenberg, D.: I. The Metabolism of Glutathione Studied with Isotopic Glycine, *J. Biol. Chem* 139: 761 - 774, 1941.
10. Waelsch H., and Rittenberg D.: The Metabolism of Glutathione Studied with Isotopic Ammonia and Glutamic Acid, *J. Biol. Chem.* 144: 53 - 58, 1942.
11. Braunstein, A.E.: *Advances in Protein Chemistry*, Vol. III, Page 1: Academic Press, New York, 1947.
12. Johnston R.B., and Block K.: The Synthesis of Glutathione in Cell - free Pigeon Liver Extracts, *J. Biol. Chem.* 179: 493 - 494, 1949.
13. Johnston R.B. , and Block K.: Enzymatic Synthesis of Glutathione, *J. Biol. Chem.* 188: 221 - 240, 1951.
14. Block, K.: The Synthesis of Glutathione in Isolated Liver, *J. Biol. Chem.* 179: 1245 - 1254, 1949.
15. Block, K. and Anker, H.S.: Synthesis of Glutathione in Isolated Liver, *J. Biol. Chem.* 169: 765 - 766, 1947.
16. Anderson, E.I. and Mosher, W.A.: Incorporation of S35 from dl-Cystine into Glutathione and Protein in the rat, *J. Biol. Chem.*, 188: 717 - 722, 1951.
17. Lindan, O. and Work, E.: Liver Glutathione and Ascorbic Acid in Dietetic Liver Necrosis of Rats, *Biochem. J.*, 48: XXXI - XXXII, 1951.
18. Binkley, F., Christensen, G.M. and Fong Chi Wu : Metabolism of Glutathione. V. An Effect of Insulin, *J. Biol. Chem.*, 192: 29 - 34, 1951.

19. Kinsey V.E., and Merrian F.C.: Studies on the Crystalline Lens. Synthesis of Glutathione in the Normal and Cataractous Rabbit Lens, A.M.A. Arch. of Ophth. 44: 370 - 377, 1950.
20. Binet L., Blanchetiere, A. and Arnaudet, A.: Synthesis of Glutathione in the Adrenal Gland, Compt. rend soc. Biol. 104: 56 - 57, 1930; C.A. 25, 3705.
21. Barron, E.S.G.: Advances in Enzymology, Page 249; Edited by Nord F.F., XI. Interscience Publishers Inc. New York, 1951.
22. Keilin, D.: Cytochrome and Intracellular Oxidase, Proc. Roy. Soc. London, B 106: 418 - 444, 1930.
23. Ames, S.R., and Elvehjem, C.A.: Enzymatic oxidation of Glutathione, J. Biol Chem. 159: 549 - 562, 1945.
24. Ames, S.R., and Elvehjem, C.A.: Enzymatic Oxidation of Glutathione, II. Studies on the Addition of Several Factors, Arch. Biochem. 10: 443 - 453, 1946.
25. Purr, A.: Studies on the Reversible Inactivation of Papain and Cathepsin, Biochem. J. 29: 5 - 20, 1935.
26. Hopkins, E.G., and Elliott, K.A.C.: The Relation of Glutathione to Cell Respiration with Special Reference to Hepatic Tissue, Proc. Roy. Soc. London, B 109: 58 - 88, 1931.
27. Mann, P.J.G.: XCV. The Reduction of Glutathione by a Liver System, Biochem. J. 26: 785 - 790, 1932.
28. Meldrum, N.U. and Tarr, H.L.A.: XV. The Reduction of Glutathione by the Warburg-Christian System. Biochem. J., 108: 115, 1935.
29. Binkley, F. and Nakamura, K.: Metabolism of Glutathione. I. Hydrolysis by Tissues of the Rat. J. Biol. Chem. 173: 411 - 421, 1948.
30. Olson, C.K. and Binkley, F.: Metabolism of Glutathione. III. Enzymatic Hydrolysis of Cysteinylglycine, J. Biol. Chem. 186: 731 - 735, 1950.
31. Binkley, F. and Olson, C.K.: Metabolism of Glutathione. IV. Activators and Inhibitors of the Hydrolysis of Glutathione, J. Biol. Chem. 188: 451 - 457, 1951.
32. Binkley, F.: Metabolism of Glutathione, Nature, 167: 888, 1951.
33. Nakamura, K. and Binkley, F.: The Enzymatic Hydrolysis of Glutathione, Federation Proc. 7: 348, 1948.
34. Binkley F. and Olson, C.K.: Nature of Enzymes Responsible for Hydrolysis of Glutathione, Federation Proc. 10: 163, 1951.
35. Hanes, C.S., Hird, F.J.R., and Isherwood, F.A.: Synthesis of Peptides in Enzymatic Reactions Involving Glutathione, Nature, London, 166: 288 - 289, 1950.
36. Hanes, C.S., Hird, F.J.R., and Isherwood, F.A.: Enzymic Transpeptidation Reaction Involving γ -glutamyl Peptides and Amino-acyl Peptides, Biochem. J. 51: 25 - 35, 1952.
37. Fruton, J.S., Johnston, R.B., and Fried, M.: Elongation of Peptide Chains in Enzyme-Catalyzed Transamidation Reactions, J. Biol. Chem. 190, 39 - 53, 1951.
38. Hopkins, F.G., and Morgan, E.J.: On the Distribution of Glyoxalase and Glutathione, Biochem. J. 39: 320 - 324, 1945.

39. Barron, E.S.G., and Singer, T.P.: Studies on Biological Oxidations. XIX. Sulfhydryl Enzymes in Carbohydrate Metabolism, J. Biol. Chem. 157: 221 - 240, 1945.
40. Singer, T.P., and Barron, E.S.G.: Studies on Biological Oxidations. XX. Sulfhydryl Enzymes in Fat and Protein Metabolism, J. Biol. Chem. 157: 241 - 253, 1945.
41. Krinsky, I., and Racher, E.: Glutathione, A Prosthetic Group of Glyceraldehyde-3-Phosphate Dehydrogenase, J. Biol. Chem. 198: 721 - 729, 1952.
42. Roughton, R.J.W. and Clark, A.M.: The Enzymes. P. 1263, Sumner, J.B. and Murback K. Vol. I Part II, Academic Press Inc., Publishers New York, 1951.
43. Barron, E.S.G., Nelson, L. and Ardao, M.I.: Regulatory Mechanisms of Cellular Respirations II. The Role of Soluble Sulfhydryl Groups as Shown by the Effect of Sulfhydryl Reagents on the Respiration of Sea Urchin Sperm, J. Gen. Physiol. 32: 179 - 190, 1948.
44. Barron, E.S.G.: Advances in Enzymology Vol. XI Page 252: 1951, Interscience Publishers, Inc. New York.
45. Mawson, C.A.: LXVII. The Influence of Animal Tissues on the Oxidation of Ascorbic Acid, Biochem. J. 29: 569 - 579, 1935.
46. Barron, E.S.G.: Advances in Enzymology, Volume XI Page 250: Interscience Publishers Inc. New York, 1951.
47. Rapkine, L.: Chemical Processes of Cellular Division, Compt. rend. 191: 871 - 874, 1930, C.A. 25: 1594.
48. Rapkine, L.: Chemical Processes during Cellular Division, L. Rapkine, Ann. physiol. physicochem. biol. 7: 382 - 417, 1931, C.A. 26: 2227.
49. Rapkine, L: Chemical Processes during the Course of Cellular Divisions. II. Nature and Kinetics of the Reaction between -SH groups and Monoiodoacetic acid, J. Chem. phys. 33: 493 - 506, 1936. E.A. 30: 7131.
50. Voegtlin, C. and Chalkely, H.W.: Chemistry of Cell Division. I. Effect of Glutathione on Cell Division in Ameba proteus, U.S. Public Health Reports 45: 3041 - 63, 1930, C.A. 25: 1000.
51. Binet, L., and Magrou, J.: The Increase of Glutathione in Tumors of Plants, Compt. rend. 192: 1415 - 6, 1931, C.A. 25: 4,300.
52. Binet, L., and Magrou, J.: Sulfur and Growth, Compt. rend. 193: 115 - 17, 1931. C.A. 25: 5439.
53. Brachet, J.: Chemical Embryology, Translated by L.S. Barth, 1950, Interscience Publishers Inc., New York.
54. Rane, L., and Subbarow, Y.: Studies on Nutritional Requirements of Hemolytic Streptococci. I. Effect of various Substances isolated from liver on Hemolytic Streptococci, Proc. Soc. Exp. Biol. and Med 38: 837 - 9, 1938.
55. Gould, R.G.: Glutathione as an Essential Growth Factor for Certain strains of Neisseria Gonorrhoea, J. Biol. Chem. 153: 143 - 150, 1944.

1. The first part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that every entry, no matter how small, should be carefully documented to ensure the integrity of the financial data. This includes recording dates, amounts, and the nature of the transactions.

2. The second part of the document outlines the procedures for reconciling the accounts. It states that the accounts should be reconciled at the end of each month to identify any discrepancies. This process involves comparing the internal records with the bank statements and ensuring that they match. Any differences should be investigated and resolved promptly.

3. The third part of the document describes the process of preparing the financial statements. It notes that the statements should be prepared on a regular basis, typically at the end of each quarter. These statements provide a summary of the financial performance of the organization and are used by management and external stakeholders to make informed decisions.

4. The fourth part of the document discusses the importance of maintaining proper documentation for all financial transactions. It states that all receipts, invoices, and other supporting documents should be kept in a secure and organized manner. This documentation is essential for auditing and for providing evidence in the event of a dispute.

5. The fifth part of the document outlines the responsibilities of the accounting department. It states that the department is responsible for ensuring that all financial transactions are accurately recorded and reported. This includes maintaining the accounting system, reconciling the accounts, and preparing the financial statements.

6. The sixth part of the document discusses the importance of staying up-to-date with changes in accounting standards and regulations. It notes that the accounting department should regularly review the latest developments in the field and ensure that the organization's accounting practices are in compliance with all applicable laws and regulations.

7. The seventh part of the document describes the process of internal control. It states that the organization should implement a system of internal control to prevent and detect errors and fraud. This system should include segregation of duties, authorization of transactions, and regular monitoring of the accounting process.

8. The eighth part of the document discusses the importance of communication between the accounting department and other departments. It notes that the accounting department should work closely with the sales, purchasing, and other departments to ensure that all transactions are properly recorded and reported. This communication is essential for maintaining the accuracy and integrity of the financial data.

9. The ninth part of the document outlines the process of budgeting. It states that the accounting department should be involved in the budgeting process to ensure that the financial data is used to create a realistic and achievable budget. This process involves analyzing the historical data and making projections for the future.

10. The tenth part of the document discusses the importance of maintaining accurate records of all financial transactions. It emphasizes that every entry, no matter how small, should be carefully documented to ensure the integrity of the financial data. This includes recording dates, amounts, and the nature of the transactions.

56. Thomas, G.W., and Cook, E.S.: Action of Phenylmercuric Nitrate. IV. The Ability of sulfhydryl compounds to protect against the germicidal action of basic phenylmercuric nitrate, J. Bact. 54: 527 - 33, 1947.
57. Barron, E.S.G.: Some Aspects of the Biological Action of Radiation, Nov. 26, 1946. U.S. Declassified Document MDDC 484, From Advances in Enzymology Vol. XI Page 256; Interscience Publishers, New York, 1951.
58. Kinsey, V.E.: The Effects of x-rays on Glutathione, J. Biol. Chem. 110: 551 - 558, 1935.
59. Barron, E.S.G., and Flood V.: Studies on the Mechanism of Action of Ionizing Radiations. VI. The Oxidation of Thiols by Ionizing Radiations, J. Gen. Physiol. 33: 229 - 41, 1950.
60. Barron, E.S.G., Dickman, S., Muntz, J.A., and Singer, T.P.: Studies on the Mechanism of Action of Ionizing Radiations. I. Inhibition of Enzymes by x-rays, J. Gen. Physiol. 32: 537 - 552, 1949.
61. Barron, E.S.G., and Dickman, S.: Studies on the Mechanism of Ionizing Radiations. II. Inhibition of sulfhydryl Enzymes by Alpha, Beta, and Gamma Rays, J. Gen Physiol 32: 595 - 605, 1949.
62. LeMay, M.: Effect of x-Radiation upon Succinoxidase of Rat Kidney, Proc. Soc. Exp. Biol. and Med. 77: 337 - 339, 1951.
63. Dale, W.M., and Davies, J.V.: Liberation of Hydrogen Sulfide by X-radiation from Cysteine and Glutathione, Biochem. J. 48: 129 - 32, 1951.
64. Feinstein, R.N.: Effect of Irradiation and of Various Reagents on Viscosity of Nucleoprotein Solutions, Proc. Soc. Exp. Biol. and Med. 76: 646 - 9, 1951.
65. Fischer, P., Landtsheer, L de and Lecomte, J.: Reduced Glutathione content of Blood and Tissues after Total Body Irradiation with Lethal Doses of x-rays, Bull soc. chem. biol. 32: 1009 - 11, 1950. C.A. 4277 g.
66. Peterson, R.D., Beatty, C.H., and West, E.S.: Effect of Total Body x-Irradiation on Glutathione Levels in Rats, Proc. Soc. Exp. Biol. and Med. 77: 747 - 49, 1951.
67. Chapman, W.H., Sipe, C.R., Eltzholtz, D.C., Cronkite, E.P., and Chambers, F.W.: Sulfhydryl - Containing Agents and the Effects of Ionizing Radiations. I. Beneficial Effects of Glutathione Injection on x-ray Induced Mortality Rate and Weight Loss in Mice, Radiology 55: 867 - 73, 1950.
68. Chapman, W.H., and Cronkite, E.P.: Further Studies of the Beneficial Effect of Glutathione on x-irradiated Mice, Proc. Soc. Exp. Biol. And Med. 75: 318 - 22, 1950.
69. Cronkite, E.P., and Chapman, W.H.: Effect of Adrenalectomy and glutathione on x-ray induced mortality in mice, Rederation Proc. 9: 329, 1950.
70. Cronkite, E.P., Brecker, G. and Chapman, W.H.: Mechanism of Protective Action of Glutathione against Whole Body Irradiation, Proc. Soc. Exp. Biol. and Med. 76: 396 - 8, 1951.
71. Cronkite, E.P., Chapman, W.H., and Brecker, G.: Relation of Clearance and Distribution of Injected Glutathione to Protection Against Radiation Injury, Proc. Soc. Exp. Biol. and Med. 76: 456 - 59, 1951.

72. Cronkite, E.P., Brecker, G., and Chapman, W.H.: Studies on the Mechanism of the Protective Action of Glutathione against Whole Body Radiation, *Mil. Surg.* 109: 294 - 307, 1951.
73. Shirai, M.: Treatment of Roentgen Intoxication by Glutathione Preparations. Nagoya Igakkai Zosshi (J. Nagoya M.A.) (Nutt, Med. Gisell, Nagoya) 54: 183 - 192, 1941 (as stated by Chapman et al *Radiology* 55: 865 - 73, 1950.
74. Mikaelson, N.: The Protective Effect of Glutathione against Radiation-induced Chromosome Aberrations *Science* 116: 172 - 4, 1952.
75. Fulton, J.D., Arnold, A.C., Danford, M.B. and Mitchell, R.B.: The Protective Effect of Chemotherapeutic Agents on a Specific Immune Status of x-radiated mice. I. A Preliminary Study. *Texas Reports on Biol. and Med.* 10: 504 - 24, 1952.
76. Benedict, S.R., and Gottschall, G.: Analysis of Whole Blood. IV. The Determination of Glutathione, *Jour. Biol. Chem.* 99: 729 - 740, 1932 - 33.
77. Bichel, J.: Studies on the Erythrocytes Content of Reduced Glutathione and its Relation to the Hematopoiesis, *Acta Medica Scandinavica* 117: 474 - 487, 1944.
78. Woodward, G.E., and Fry, E.G.: The Determination of Glutathione, *J. Biol. Chem.* 97: 465 - 482, 1932.
79. Dohan, J.S., and Woodward, G.E.: Electrolyte Reduction and Determination of Oxidized Glutathione, *J. Biol. Chem.* 129: 393 - 403, 1939.
80. Binkley, F., Fujii, S., and Kimmell, J.R.: Metabolism of Glutathione. II. Determination of Glutathione and products of its Hydrolysis in Blood, *J. Biol. Chem.* 186: 159 - 162, 1950.
81. Grunert, R.R., and Phillips, P.H.: A Modification of the Nitroprusside Method of Analysis for Glutathione, *Arch. Biochem.* 30: 217 - 225, 1951.
82. Thompson, R.H.S., and Watson, D.: The Nitroprusside Method for the Determination of Blood Glutathione, *J. Clin. Path.* 5: 25 - 29, 1952.
83. Bidmead, D.S., and Watson, D.: The Determination of Blood Glutathione by Amperometric Titration, *J. Clin. Path.* 5: 30 - 35, 1952.
84. Sullivan, M.X., and Hess, W.C.: The Determination of Cystine in Urine, *J. Biol. Chem.* 116: 221 - 232, 1936.
85. Benesch, R.E., and Benesh, R.: Amperometric Determination of Soluble Mercapto Groups (Glutathione) in Blood and Tissues, *Arch. Biochem.*, 28: 43 - 47, 1950.
86. Hutchin, M.E., Harper, H.A., Margen, S. and Kinsell, L.W.: Microbiological Determination of Cystine, Cysteine and Glutathione in Plasma, *J. Biol. Chem.* 185: 839 - 843, 1950.
87. Bânet, L. and Weller, G.: Total Tissue Glutathione-Method of Determination and Distribution in the Tissues of Normal Animals, *Bull. soc. Chem. Biol.* 18: 358 - 74, 1936,
88. Bruckmann, G. and Wertheimer, E.: Alloxan Studies: The Action of Alloxan Homologues and Related Compounds, *J. Biol. Chem.* 168: 241 - 256, 1947.
89. Lazarow, A., Patterson, J.W., and Cooperstein, S.J.: "305" Method for the Determination of Glutathione, Not Yet Published.

90. Gabbe, E.: Soluble Sulfur Compounds in Blood Corpuscles, *Klin. Wochschr*, 8: 2077 - 81, 1929, C.A. 24: 5356.
91. Varela, K., Apolo, E. and Vilar, K.: Glutathione in the Blood in Pathological Conditions, *Klin. Wochschr* 9: 1029 - 30, C.A. 24: 4332.
92. Blyakher, Ya. I.: Glutathione in the Venous Blood after the Drawing of Blood from Rabbits and after the Loss of Blood in Man, *Therap. Archives U.S.S.R.* 17: 127 - 30, 1939, C.A. 35: 4080.
93. Kandel, E.V., and Le Roy, G.V.: The Blood Glutathione in Hematologic Diseases, *Jour. Lab. and Clin. Med.* 24: 669 - 677, 1939.
94. Bichel, J.: Studies on the Erythrocyte Content of Reduced Glutathione and its Relation to the Hematopoiesis, *Acto Medica Scand.* 117: 474 - 487, 1944.
95. Shultze, M.O., and Elvehjem, C.A.: Studies on the Glutathione Content of Blood in Nutritional Anemia, *J. Biol. Chem.* 116: 711 - 716, 1936.
96. Miyachi, S.: Blood Glutathione in Chronic Experimental Anemia, *Japan J. Med. Sci. II Biochem* 3: 257 - 62, 1937, C.A. 32: 3807, 3.
97. Pernokis, E.W., and Freeland, M.R.: Blood Chemistry Determinations in Pernicious Anemia, *J. Lab. and Clin. Med.* 26: 1177 - 1880, 1940.
98. Srikantia, C., Rao, C.K., and Row, T.P.: Glutathione in Anemia, *Proc. Indian Acad. Sci. II B* 257 - 266, 1940, C.A. 34: 8034, 7.
99. Dogliotti, G.C., and Castellani, T.: Glutathione and Anemias, *Boll. Soc. ital. biol. sper.* 10: 521 - 3, 1935, C.A. 29: 8121, 8.
100. Platt, R.: The Blood Glutathione in Disease, *Brit. J. Exptl. Path.* 12, 139 - 143, 1931.
101. Gurevich, T.S.: Glutathione in Pulmonary and Cardiac Disorders, *Sovet. Vrachelnyi Zhur* 41: 1477 - 82, 1937, C.A. 33: 9429, 8.
102. Klotz, R.: The Behavior of Glutathione in Heart Insufficiency, *Klin. Wochschr*, 18: 1466 - 8, 1939, C.A. 34: 7437, 6.
103. Aisenberg, A.A., and Khatskevich, K.M.: Blood Glutathione during Decompensation of Blood Circulation, *J. Med. Ukraine* 7: 291 - 310, 1937, C.A. 32: 9215, 5.
104. Blyakher, Ya. I.: The Glutathione in the Blood of Individuals who are Ill, *Klin. Med. (U.S.S.R.)* 16: 996 - 1001, 1938, C.A. 34: 7396, 1.
105. Rabboni, F., and Buttitta, P.L.: Glutathione after Lobectomy and Pneumectomy in Dogs and Rabbits, *Boll. soc. ital. biol. sper.* 20: 794 - 96, 1945. C.A. 40: 66091, 1.
106. Kosyakov, K.S.: Glutathione in the Blood Under Certain Anoxic Conditions, *J. Physiol. U.S.S.R.* 23: 301 - 309, 1937. C.A. 33: 709, 1.
107. Hosoi, T.: The Chemistry of the Organism in Asphyxia and Recovery and the Influence of Some Endocrine Glands, *Mitt. Med. Akad. Kioto.* 25: 711 - 14, 1929, C.A. 35: 1100, 7.

1. The first part of the paper discusses the importance of the study and the objectives of the research. It also mentions the scope of the study and the limitations of the study.

2. The second part of the paper discusses the methodology used in the study. It mentions the data sources and the data collection methods used in the study.

3. The third part of the paper discusses the results of the study. It mentions the findings of the study and the conclusions drawn from the study.

4. The fourth part of the paper discusses the implications of the study. It mentions the practical implications of the study and the theoretical implications of the study.

5. The fifth part of the paper discusses the future research. It mentions the areas for future research and the suggestions for future research.

6. The sixth part of the paper discusses the conclusion of the study. It mentions the overall findings of the study and the conclusions drawn from the study.

7. The seventh part of the paper discusses the references. It mentions the sources used in the study and the references cited in the study.

8. The eighth part of the paper discusses the appendix. It mentions the additional information provided in the study and the appendix included in the study.

9. The ninth part of the paper discusses the bibliography. It mentions the sources used in the study and the references cited in the study.

10. The tenth part of the paper discusses the index. It mentions the topics covered in the study and the index provided in the study.

1108. Chervyakovskii, N. Ya and Bruk, E.M.: Changes in the Glutathione Level in the Blood in Diseases which are accompanied by a disturbance of the water economy, Chem. Zentr. I, 4072, 1938, C.A. 33: 9429, 8.
1109. Paskeau, T.G.: Glutathione Values at Different Altitudes, J. Med. Ukraine 7: 69 - 72, 1937, C.A. 31: 8286.
1110. Malkin, S.I., Makarova, T.A. and Sarbeteva, W.S.: The Dynamics of Glutathione in Disturbed Circulation, Zr. ges. exptl. Med. 97: 523 - 33, 1936, C.A. 32: 3464, 4.
1111. Delrue, G. and Vischer, E.: Biochem. Z. 236: 174, 1931 as stated by Oberst, F.W. and Woods, E.B.: Studies in Glutathione, J. Biol. Chem. 111: 1 - 7, 1935.
1112. Gabbe E., L. ges. exp. Med. 69: 392, 1930, Oberst F.W. and Woods, E.B. As stated by: Studies in Glutathione, J. Biol. Chem. 111: 1 - 7, 1935.
1113. Vacca, C.: Variations of Glutathione in Man at Lowered Barometric Pressures, Boll. Soc. ital. Biol. sper. 20: 71 - 4, 1945, C.A. 40: 5820, 8.
1114. Omura, T., and Ohida, M.: Effect of CO and KCN on the Oxidation-Reduction System in the Living Organism, Chem. Zentr. II: 562 - 3, 1942, C.A. 37: 6344, 8.
1115. Yoshizawa, S.: Hydrocyanic Acid and Carbon Monoxide Poisoning, Tohoku Ig. Z., 19: 855 - 955, 1936, C.A. 32: 659, 2.
1116. Handovsky, H.: Glutathione as Intermediary in Metabolism and Activity, Klin. Wochschr 9: 937 - 8, 1930, C.A. 24: 4542.
1117. Komissarov, A.N.: Compensating Factors of Oxidative Processes in the Organism in Anemia, Klin. Med. (U.S.S.R.) 23: 56 - 63, 1945, C.A. 41: 7498, c.
1118. Hughes, Walter J. Jr.: Protein Mercaptides - Cold Spring Harbor Symposium, Quant. Biol. 14: 79 - 84, 1949.
1119. Ingbar, S.H. and Kass, E.H.: Sulfhydryl Content of Normal Hemoglobin and Hemoglobin in Sick Cell Anemia, Proc. soc. Exp. Biol. and Med. 77: 74 - 76, 1951.
1120. Riggs, A.F.: Sulfhydryl Groups and the Interaction between the hemes in Hemoglobin, Jour. Gen. Physiol. 36: 1 - 16, 1952.
1121. Hill, R. and Wolvekamp, H.P.: The Oxygen Dissociation Curve of Hemoglobin in Dilute Solution, Proc. Roy. Soc. London Series B 120: 484 - 95, 1936.
1122. McCarthy, E.F.: A Comparison of Foetal and Maternal Haemoglobins in the Goat, J. Physiol. 80: 206 - 12, 1934.

123. Hall, F.G.: A Spectroscopic Comparison of Foetal and Maternal Blood of the Rabbit and Goat, J. Physiol, 82: 33 - 37, 1934.
124. Jacobs, H.R.: Hypoglycemic Action of Alloxan, Proc. Soc. Exp. Biol and Med. 37: 407 - 9, 1937.
125. Bailey, C.B. and Bailey, O.T.: The Production of Diabetes Mellitis in Rabbits with Alloxan, J.A.M.A. 122: 1165 - 1166, 1943.
126. Dunn, J.S., Shehan, H.L. and McLetchie, N.G.B.: Necrosis of Islets of Langerhans Produced Experimentally, Lancet, 244: 484 - 487, 1943.
127. Goldner, M.G. and Gomori, G.: Alloxan Diabetes in the Dog, Endocrinology 33: 297 - 308, 1943.
128. Gomori, G. and Goldner, M.G.: Production of Diabetes Mellitis in Rats with Alloxan, Proc. Soc. Exp. Biol. and Med. 54: 287 - 290, 1943.
129. Brunschwig, A. and Allen, J.G.: Specific Injurious Action of Alloxan Upon Pancreatic Islet Cells and Convoluted Tubules of the Kidney, Cancer Research 4: 45 - 54, 1944.
130. Bailey, C.C. Bailey, O.T. and Leech, R.S.: Alloxan Diabetes with Diabetic Complications, New Eng. Jour. Med. 230: 533 - 536, 1944.
131. Brunschwig, A., Owens, F.M., Allen, J.G. and Thorton, T.F.: Alloxan in the Treatment of Insulin Producing Islet Cell Carcinoma of Pancreas, J.A.M.A. 124: 212 - 216, 1944.
132. Griffith, J.E.Jr., Jackson, R.L. and Janes, R.G.: Action of Alloxan on a Hypoglycemic Infant, Paediatrics 7: 616 - 622, 1951.
133. Talbot, N.B., Crawford, J.D. and Bailey, C.C.: Use of mesoxalyl urea (alloxan) in Treatment of Infants with convulsions due to idiopathic hypoglycemia, Paediatrics 1: 337 - 345, 1948.
134. Goldner, M.G.: Alloxan Diabetes. Its Production and Mechanism, Bull. New York Acad. Med. 21: 44 - 55, 1945.
135. Bailey O.T., Bailey, C.C., Hagan, W.H.: Alloxan Diabetes in the Rabbit. A Consideration of Morphologic and Physiologic Changes, Amer. Jour. Med. Sc. 208; 450 - 461, 1944.
136. Gomori, G. and Goldner, M.G. : Acute Nature of Alloxan Damage, Proc. Soc. Exp. Biol. and Med. 58: 232 - 233, 1945.
137. Bailey, C.C., Collins-Williams, J. and Le Compte, P.M.: Effect of Alloxan in Rabbits with Temporary Occlusion of the Arteries of the Pancreas, Proc. Soc. Exp. Biol. and Med. 71; 580 - 583, 1949.
138. Ridout, J.H., Ham, A.W. and Wrenshall, C.A.: The Correlation of the Insulin Content and the histological picture of the Pancreas at intervals after the administration of alloxan, Science 100: 57 - 58, 1944.

139. Bell, H.J. and Best, C.H. and Haist, R.E.: The Effect of Partial Pancreatectomy on the concentration of Insulin in the Pancreatic Remnant, Jour. Physiol. 101: 11 - 26, 1942.
140. Campbell, J. and Best, C.H.: Production of Diabetes in Dogs by Anterior - Pituitary Extracts, Lancet, 234: 1444 - 1445, 1938.
141. Scott, D.A., and Fisher, A.M.: The Insulin and the Zinc Content of Normal and Diabetic Pancreas, J. Clin. Invest. 17: 725 - 728, 1938.
142. Richardson, K.C. and Young, F.G.: Histology of Diabetes Induced in Dogs by Injection of Anterior - Pituitary Extracts, Lancet 234: 1098 - 1101, 1938.
143. Richardson, K.C.: The influence of diabetogenic anterior pituitary extracts on the islets of Langerhans in dogs, Proc. Roy. Soc. London, B128: 153 - 168, 1939 - 40.
144. Lukens, F.D.W. and Dohan, F.C.: Pituitary Diabetes in the Cat; Recovery following Insulin or Dietary Treatment, Endocrinology 30: 175 - 202, 1942.
145. Woerner, C.A.: Studies of the Islands of Langerhorn after Continuous Intravenous Injection of Dextrose, Anatomical Record 71: 33- 49, 1938.
146. Dohan, F.C. and LUKENS, F.D.W.: Lesions of the Pancreatic Islets Produced in Cats by Administration of Glucose, Science 105: 183, 1947.
147. Leech, R.S. and Bailey, C.C.: Blood Alloxan and Blood Glutathione in rabbits injected with alloxan, J. Biol. Chem 157: 525 - 542, 1945.
148. Weinglass, A.R., Frame, E.G. and Williams, R.H.: Inhibition of Diabetogenic Action of Alloxan, Proc. Soc. Exp. Biol and Med. 58: 216 - 219, 1945.
149. Lazarow, A.: Protective Effect of Glutathione and cysteine against alloxan diabetes in the rat, Proc. Soc. Exp. Biol. and Med. 61: 441 - 447, 1946.
150. Palay, L. and Lazarow, A.: Protection against diabetes and production of Hepatic Necrosis by use of Cysteine and Alloxan in the Rat, Anatomical Record 96: 55 - 69, 1946.
151. Curtis, A.C. and Newburgh, L.H. and Thomas F.H.: The Toxic action of cystine on the kidney, Arch. Int. Med. 39: 817 - 827, 1927.
152. Earle, D.P. and Victor, J. : Cirrhosis of the Liver caused by excess Dietary Cystine, J. Exp. Med. 73: 161 - 172, 1941.
153. Gyorgy, P. and Goldblatt, H.: Observations on the Conditions of dietary Hepatic Injury in rats, J. Exp. Med. 75: 355 - 368, 1942.
154. Lazarow, A. Patterson, J.W. and Levey, S: The Mechanism of Cysteine and Glutathione Protection against alloxan diabetes, Science 108: 308 - 309, 1948.

The first part of the report deals with the general situation of the country and the progress of the work during the year. It is followed by a detailed account of the various projects and the results achieved. The report concludes with a summary of the work done and a list of the names of the persons who have contributed to it.

THE SECRETARY


155. Patterson, J.W., Lazarow, A. and Levey, S.: Alloxan and dialuric acid: Their Stabilities and Ultraviolet Absorption Spectra, J. Biol. Chem. 177: 187 - 196, 1949.
156. Patterson, J.W., Lazarow, A. and Levey, S.: Reactions of Alloxan and Dialuric Acid with the sulphhydryl group, J. Biol. Chem. 177: 197 - 204, 1949.
157. Bruckman, G. and Wertheimer, E.: Diabetogenic Action of Alloxan Derivatives, Nature 155: 267 - 268, 1944.
158. Archibald, R.M.; Methods for the Determination of Alloxan, together with observations of Certain Properties of Alloxan, J. Biol. Chem. 158: 347 - 373, 1945.
159. Griffiths, M.: Uric Acid Diabetes, J. Biol. Chem. 172: 853 - 854, 1948.
160. Griffiths, M.: The Effect of Alloxan in Methionine - and Cystine - deficient Guinea pigs, Endocrinology 48: 117 - 118, 1951.
161. Collins-Williams, J. , Renold, A.E. and Marble, A: Attempts to Produce Diabetes in Guinea Pigs by Alloxan and Pancreatectomy, Endocrinology 46: 1 - 13, 1950.
162. Scott, C.C., HARRIS, P.N. and Chen, K.K.: Effects of Alloxan in Birds, Endocrinology 37: 201 - 207, 1945.
163. Grunert, R.R., and Phillips, P.H.: Uric Acid Diabetes in the Rat, Proc. Soc. Exp. Biol. and Med. 76: 642 - 645, 1951.
164. Houssay, B.A. and Martinez, C.: Prevention and Cure of alloxan diabetes by Thiouracils or cysteine, Rev. Soc. Argent. Biol. 24: 63 - 72, 1948, C.A. 43: 5118, c.
165. Houssay, B.A. and Martinez, C.: Preventive or Curative action of Theouracils and cysteine in diabetes produced by subtotal Pancreatectomy, Rev. Soc. Argent. Biol. 24: 123 - 129, 1948, C.A. 43: 5118, f.
167. Capra, P.: Basal Metabolims and blood Glutathione in normal persons treated with Methylthiouracil, Arch. sci. med. 88: 285 - 291, 1949. C.A. 44: 1611, c.
166. Martinez, C.: Increase in Tissue Sulphydryl groups by treatment with Thiouracils or cysteine, Rev. Soc. Argent, Biol. 24: 86 - 91, 1948. C.A. 43: 5118, e.
168. Capra, P.: Basal Metabolism and blood Glutathione in normal persons treated with Propylthiouracil. Arch Sci. Med. 88: 361 - 367, 1949, C.A. 44: 2120, i.
169. Prina, C.: Action of Thiouracil on blood glutathione in the rabbit, Bull. Soc. ital. biol. sper. 22: 950 - 951, 1946. C.A. 41: 6335, e.
170. Domingo, C. Masa: Effect of Thiourea on total oxidized and reduced glutathione in the blood, Trabajos inst. na cl cienc Med. 6: 537 - 542, 1945, 6.
171. Lazarow, A.; Further Studies of Effect of Sulphur Compounds on Production of Diabetes with alloxan, Proc. Soc. Exp. Biol. and Med. 66: 4 - 7, 1947.

172. Du Vigneaud, V.: The Sulfur of Insulin, J. Biol. Chem. 75: 393 - 405, 1927.
173. Du Vigneaud, V.: The Role which Insulin has played in our concept of Protein Hormones, and a consideration of certain phases of the Chemistry of Insulin, Cold Spring Harbor Symposium VI: 275 - 285, 1938.
174. Patterson, J.W.: The Diabetogenic effect of dehydroascorbic and dehydroisoascorbic acids, J. Biol. Chem. 183: 81 - 88, 1950.
175. Patterson, J.W., and Lazarow, A.: Sulfhydryl protection against dehydroascorbic acid diabetes, J. Biol. Chem. 186: 141 - 144, 1950.
176. Banerjee, S.: Vitamin C and Carbohydrate Metabolism, Nature, 152: 329, 1943.
177. Banerjee, S.: Relation of Scurvy to Histological Changes in the Pancreas, Nature 153: 344 - 345, 1944.
178. Banerjee, S. and Ghosh, N.C.: Relation of Scurvy to Glucose Tolerance Test, Liver Glycogen, and Insulin Content of pancreas of guinea pigs, J. Biol. Chem. 168: 207 - 211, 1947.
179. Banerjee, S.: Deb. C. and Delavady, B.: Effect of Scurvy on Glutathione and Dehydroascorbic acid in guinea pig tissues, J. Biol. Chem., 195: 271 - 276, 1952.
180. Nath, M.C. and Brahmachari : Experimental Hyperglycemia by injection of intermediary fat metabolism products in rabbits, Nature 154: 487 - 488, 1944.
181. Nath, M.C. and Brahmachari: Inactivation of Insulin by Intermediary Fat Metabolism Products, Nature 157: 336, 1946.
182. Nath, M.C. and Brahmachari, H.D.: Relation of intermediary metabolites to the lowering of the Potency of pancreatic insulin in the animal system, Nature 161: 18, 1948.
183. Nath, M.C. and Chakraborty : Progressive Decreased Glucose Tolerance and Glycogen Storage following acetoacetate injections; prevention by insulin and Amellin, Proc. Soc. Exp. Biol and Med. 75: 326 - 331, 1950.
184. Nath, M.C., Chakraborty, C.H., Hatwalne, V.G. and Laul, K.S.: Species Differences in the Biosynthesis of Vitamin C and Response to Diabetogenic substances, Nature 162: 660 - 661, 1948.
185. Nath, M.C. and Chakraborty, C.H.: Acetoacetate - Induced changes in blood lactic and blood ascorbic acids; prevention by insulin and Amellin, Proc. Soc. Exp. Biol. and Med. 78: 369 - 371, 1951.
186. Nath, M.C. and Hatwalne, V.G.: Effect of Acetoacetic Acid on reduced glutathione content of blood in rabbits, Nature 166: 692 - 693, 1950.

187. Nath, M.C., Hatwalne, V.G., and Gadgel, J.S.: Progressive Depletion in the Reduced Glutathione content of the blood following acetoacetate injections, *Biochem. J.* 53:479 - 481, 1953.
188. Nath, M.C., Gadgel, J.S. and Hatwalne, N.G.: Studies on alloxan diabetes. I. Increase of susceptibility caused by acetoacetate, *Biochem. J.* 53: 481 -483, 1953.
189. Lazarow, A.: The sulfhydryl metabolism of the beta cell and its relationship to the development of diabetes, *Biol. Bull.* 95: 239, 1948.
190. Bell, H.J. and Best, C.H. and Haist, R.E.: The Effect of partial pancreatectomy on the concentration of insulin in the pancreatic remnant, *Jour. of Physiol.* 101: 11 - 16, 1942.
191. Richardson, K.C. and Young, F.G.: The "Pancreatropic" Action of anterior pituitary Extracts, *J. Physiol.* 91: 352 - 363, 1937.
192. Woerner, C.A.: Studies of the Islands of Langerhans of Dextrose Anatomical Record 71: 33 - 49, 1938.
193. Dohan, F.C. and Lukens, F.D.W.: Lesions of the Pancreatic islets produced in cats by administration of glucose. *Science* 105: 183, 1947.
194. Campanacci, D.: Carbohydrate Metabolism and soluble sulfur compounds in red cells and tissues, *Klin. Wochschr* 9: 1212 - 3, 1930. *C.A.* 24: 5816.
195. Varela, K., Apolo, E., and Vilar, K.: Glutathione in the blood in pathological conditions, *Klin. Wochschr*, 9: 1029 - 30, 1930. *C.A.* 24: 4332.
196. Dogliotti, G.C., and Meloni, O.: Glutathione and Diabetes, *Boll. soc. ital biol. sper.* 10: 523 -5, 1935. *C.A.* 29: 8121, 9.
197. Stock, R., Currence, J.D., and Swanson, E.: The Uric Acid and Glutathione Content of the Blood in Diabetes Mellitis, *J. Clin. Endocrinology* 10: 313 - 317, 1950.
198. Caren, R. and Carne, H.O.: Blood glutathione level and its response to insulin, *Amer. Jour. Med. Sc.* 221: 307 - 313, 1951.
199. Illing, E.K.B., Gray, C.H. and Lawrence, R.D.: Blood glutathione and non glucose reducing substances in diabetes, *Biochem. J.* 48: 637 - 640, 1951.
200. Binkley, F., Fujii, S. and Rimmell, J.R.: Metabolism of glutathione II. Determination of glutathione and products of its hydrolysis in blood, *J. Biol. Chem.* 186: 159 - 162, 1950.
201. Holten, C. and Lundbach, K.: Metabolic and renal diabetes following the administration of ACTH (Study of blood sugar, urine sugar, and blood glutathione during action of ACTH), *Scandinav. Jour. Clin. and Lab. Invest.* 2: 317 - 321, 1950.

202. Conn, J.W., Louis, L.H. and Wheeler, C. E.: Production of Temporary Diabetes by purified Adrenocorticotrophic hormone in man - relation to uric acid meta, J. Laband Clin. Med. 33: 651 - 661, 1948.
203. Evans, H.M., Meyer, K., Simpson, M.E., and Reichart, F.L.: Disturbance of Carbohydrate metabolism in Normal Dogs injected with the Hypophyseal growth hormone, Proc. Soc. Exp. Biol and Med. 29: 857 - 858, 1931 - 2.
204. Baumann, E.J., and Marine, D.: Glucosuria in rabbits following injections of Sline Extract of Anterior Pituitary, Proc. Soc. Exp. Biol. and Med. 29: 1220 - 1223, 1932.
205. Hess, W.C., Kyle, L.H., and Doolan, P.D.: Effect of Administration of ACTH and Cortisone upon blood glutathione levels, Proc. Soc. Exp. Biol. and Med. 76: 418 - 422, 1951.
206. Conn, J.W., Louis, L.H. and Johnston, M.W.: Metabolism of uric acid glutathione and nitrogen and excretion of II - oxysteroids and 17 - ketosteroids during induction of diabetes in man with pituitary adrenocorticotrophic hormone, Jour. Lab. and Clin. Med. 35, 255 - 269, 1949.
207. Levin, M.H., Adams, W.S., Beck, W.S., Goldman, R. and Bassett, S.H.: Prolonged treatment of a case of periarteritis Nodosa with ACTH: The Effective dose as measured by metabolic balances, J. Clin. Endocr. 11: 375 - 394, 1951.
208. Joiner, C.L.: Blood glutathione levels and carbohydrate Tolerance during ACTH Therapy, B.M.J. II 642 - 643, 1952.
209. Forsham, P.H., Horn, G.W., Prunty, F.T.G. and Hills, A.G.: Clinical studies with pituitary Adrenocorticotropin, J. Clin. Endocrinol. 8: 15 - 66, 1948.
210. Sayers, G., Burns, T.W., Tyler, F.H., Jager, B.V., Schwartz, T.B., Smith, E.L., Samuels, L.T., and Davenport, H.W.: Metabolic actions and fate of intravenously administered adrenocorticotrophic Hormone in man, J. Clin. Endocr. 9: 593 - 614, 1949.
211. Best, C.H., Campbell, J., Haist, R.E., and Ham, A.W.: The effect of insulin and anterior pituitary extract on the insulin content of the pancreas and the histology of the Islets, J. Physiol. 101: 17 - 26, 1942.
212. Haist, R.E.: Factors affecting the Insulin Content of the pancreas, Physiol. Reviews 24: 409 - 444, 1944.
213. Atkinson, R.R.B.: Acromegaly, Descriptions of Papers reported in 1935, 1936, 1937, Endocrinologie 20: 245 - 257, 1938, B.C.A, A, III, 1005, 1938

214. Ennor, A.H.: The influence of anterior pituitary extracts on the content and rate of Oxidation of Glutathione in Tissues, Austral. Jour. Exp. Biol. 17: 173 - 181, 1939.
215. Goss, H. and Gregory, P.W.: Glutathione Concentration of livers and muscles of rats following injection of hypophysial growth Hormone, Proc. Soc. Exp. Biol. and Med. 32: 681 - 683, 1935.
216. Kass, E.H., Ingbar, S.H., and Findland, M.: Renal Glycosuria induced by Adrenocorticotropic Hormone, Proc. Soc. Exp. Biol. and Med. 73: 669 - 672, 1950
217. Ingbar, S.H., Otto, J.F., and Ross, E.H.: Effect of ACTH on blood glutathione and sulfhydryl content of liver and kidney in rats, Proc. Soc. Exp. Biol. and Med. 77: 20 - 23, 1951.
218. Grunert, R.R. and Phillips, P.H.: Effect of Stress and the Adrenocorticotrophic Hormone on Blood Glutathione, Amer. J. Physiol. 165: 574 - 579, 1951
219. Hennaman, D.H., and Aetschule, M.D.: Immediate effects of Shock Therapies, Epinephrine and ACTH on blood glutathione levels of psychotic patients, J. applied Physiol. 3: 411 - 416, 1951.
220. Conn, J.W., Louis, L.H. and Johnstona, M.W.: Alleviation of Experimental Diabetes by the Administration of Reduced Glutathione, Science 109: 279 - 280, 1949.
221. Ingle, D.J.: The production of glycosuria in the Normal rat by means of 17 - hydroxi-II-dehydrocorticosterone, Endocrinology, 29: 649 - 652, 1941.
222. Lazarow, A.: Glutathione Potentiation of Cortisone-induced Glycosuria in the rat, Proc. Soc. Exp. Biol. and Med. 74: 702 - 705, 1950.
223. Lazarow, A. and Berman, J.: The production of diabetes in rats with cortisone and its relation to glutathione, Anat. Rec. 106: 215 - 216, 1950.
224. Lazarow, A.: The Relation of Glutathione to the Diabetogenic effect of Adrenal Steroids, Diabetes, 1: 171 - 182, 1952.
225. Sprague, R.G., Power, M.H., Mason, H.L., Mathieson, D.R., Hench, P.S., Kendall, E.C., Slocumb, C.H., and Palley, H.F.: Observations on the Physiologic effects of cortisone and ACTH in man, Arch. Int. Med. 85: 199 - 258, 1950.
226. Ingle, D.J., Sheppard, R., Evans, J.S. and Kuzenga, M.H.: A comparison of Adrenal Steroid Diabetes and Pancreatic Diabetes in the rat, Endocrin. 37: 341 - 356, 1945.
227. Lukens, F.D.W., and Dohan, F.C.: Pituitary Diabetes in the cat; recovery following insulin or dietary treatment, Endocrin. 30: 175 - 202, 1942.



228. Sprague, R.G., Priestley, J.T. and Dockerty, M.B.: Diabetes Mellitus without other Endocrine manifestations in a case of tumor of the Adrenal cortex, *J. Clin. Endocrin.* 3: 28 - 32, 1943.
229. Russi, S., Blumenthal, H.T. and Gray, S.H.: Small Adenoma~~s~~ of the adrenal cortex in Hypertension and diabetes, *Arch. Int. Med.* 76: 284 - 291, 1945.
230. Binet, L. and Poutonnet, M.: Addison's Disease and Blood Glutathione, *Ann d' endocrinol.* 4: 111 - 113, 1943. C.A.38: 5939, 5.
231. Binet, L. and Poutonnet, M.: Addison's Disease and Blood Glutathione, *Chem. Zentr. II*: 1725, 1943, C.A.38;5939,5.
232. Maloberti, U.: Glutathione Content of the Blood of Hypothyroid Patients, *Ras studi psichiatr.* 24: 235 - 242, 1935. C.A. 31: 7999,3.
233. Maloberti, U.: Glutathione Content of the Blood of Hypothyroid Patients, *Ber. ges. physiol. expth. Pharmakol*, 89: 117, 1935. C.A. 31: 7999, 3.
234. Braier, B.: Glutathione and Experimental Hyperthyroidism *Anales form. Bioquim (Bionos Aires)* 7: 73 - 86, 1936, C.A. 31: 3152, 8.
235. Zunz, E. and Vesselovsky, O: Thyroxine and Parathyroid Extracts on glutathione, *Compt. rend. trav. lab. Carlsberg, Seachim*,22: 562 - 570, 1938, C.A. 32: 6303, 3.
236. Livieratos, S.S.: Blood glutathione and thyroid activity, *Compt. rend. soc. biol.* 129: 299 - 301, 1938, C.A. 33: 740, 8.
237. Coccialanza, P.: Glutathione in the Tissue under various Experimental Conditions, *Boll. soc. Ital. biol. sper.* 14: 307 - 309, 1939, C.A. 33: 7864,3.
238. Mutel, I.I.: Comparison of Hemochemical Symptomatology and Basal Metabolism, *Rev. Med. Militar* 32: 464, 473, 1943, C.A. 39; 3059, 8.
239. Capra, P.: Glutathione in the blood and basal Metabolism in Experimental hyperthyroidism and hypothyroidism (Thyroxine and Methylthiouracil), *Biol. Soc. Me. chir. Pavia*, 61: 7, 1947, C.A. 43: 5119, g.
240. Cinelli, A.P.: Hepatic Insufficiency and S. Metabolism in the Liver, *Rev. univ. na.cl. Cordoba* 28: 1495 - 1507, 1941. C.A. 36: 6643, L.
241. Edwards, S. and Westerfield, W.W.: Blood and Liver Glutathione During Protein Deprivation, *Proc. Soc. Exp. Biol. and Med.* 79: 57 - 59, 1952.
242. Leaf, G. and Neuberger, A: Effect of Diet on the Glutathione content of the Liver, *Biochem. J.* 41: 250 - 257, 1947.
243. Brunschwig, A., Johnson, C. and Nichols, S.: Carbon Tetrachloride Injury of the Liver. The Protective Action of Certain Compounds, *Proc. Soc. Exp. Biol. and Med.* 60; 388 - 391, 1945.

244. Malenkova, K.M.: Glutathione in Leukaemia, *Klin, Med. U.S.S.R.* 16: 1007 - 9, 1938, C.A.34: 1382, 6.
245. Binet, L., Bernard, J., Wallers, G. and Mathe, G.: Blood glutathione Levels in acute Leukaemia, *Press Medicale* 60: 961 - 3, 1952.
246. Contopoulos, A.N., and Anderson, H.H.: Sulfhydryl Content of blood cells in Dyscrasias, *J. Lab. and Clin. Med.* 36: 929 - 941, 1950.
247. Denny-Brown, D. and Porter, H.H.: The effect of BAL (2,3-dimercaptopropanol) on Hepatolenticular Degeneration (Wilson's Disease), *N. England J.M.* 245: 917 - 925, 1951.
248. Grunert, R.R., Meyer, J.H. and Phillips, P.H.: Effect of Dietary Electrolyte Deficiencies on the Blood and Liver Levels of Reduced glutathione, *Amer. J. Physiol.* 165: 568 - 573, 1951.
249. Grunert, R.R., and Phillips, P.H.: Sodium and its relation to alloxan diabetes, *J. Biol. Chem.* 181: 821 - 827, 1949.
250. Zwemer, R.L., Vollmer, E.P. and Carey, M.M., Glutathione Protection against potassium in mice, *Amer. J. Physiol.* 164: 766 - 769, 1951.
251. Carey, M.M., Vollmer, E.P., Zwemer, R.L., and Spence, D.L.: Decrease of Adrenal Ascorbic Acid and Cholesterol in Rat and Guinea pigs following large doses of glutathione. *Amer. J. Physiol.* 164: 770 - 773, 1951.
252. Kety, S.S., Polis, B.D., Nadler, C.S., and Schmidt, C.F.: The Blood flow and oxygen consumption of the Human Brain in Diabetic Acidosis and Coma, *J. Clin. Invest.* 27: 500 - 510, 1948.

B29767